

Central Lancashire Online Knowledge (CLoK)

Title	Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis
Туре	Article
URL	https://clok.uclan.ac.uk/19995/
DOI	https://doi.org/10.1371/journal.pmed.1002389
Date	2017
Citation	Tucker, Katherine L., Sheppard, James P., Stevens, Richard, Bosworth, Hayden B., Bove, Alfred, Bray, Emma, Earle, Kenneth, George, Johnson, Godwin, Marshall et al (2017) Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta- analysis. PloS medicine, 14 (9). e1002389. ISSN 1549-1676
Creators	Tucker, Katherine L., Sheppard, James P., Stevens, Richard, Bosworth, Hayden B., Bove, Alfred, Bray, Emma, Earle, Kenneth, George, Johnson, Godwin, Marshall, Green, Beverly B. and Et, Al

It is advisable to refer to the publisher's version if you intend to cite from the work. https://doi.org/10.1371/journal.pmed.1002389

For information about Research at UCLan please go to http://www.uclan.ac.uk/research/

All outputs in CLoK are protected by Intellectual Property Rights law, including Copyright law. Copyright, IPR and Moral Rights for the works on this site are retained by the individual authors and/or other copyright owners. Terms and conditions for use of this material are defined in the <u>http://clok.uclan.ac.uk/policies/</u>



Citation: Tucker KL, Sheppard JP, Stevens R, Bosworth HB, Bove A, Bray EP, et al. (2017) Selfmonitoring of blood pressure in hypertension: A systematic review and individual patient data metaanalysis. PLoS Med 14(9): e1002389. https://doi. org/10.1371/journal.pmed.1002389

Academic Editor: Kazem Rahimi, University of Oxford, UNITED KINGDOM

Received: October 19, 2016

Accepted: August 10, 2017

Published: September 19, 2017

Copyright: © 2017 Tucker et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: Data were obtained from third parties for this analysis. Several of the participating studies required specific data sharing agreements from their host institution. Current agreements are for the purposes of this analysis alone and as such new approval would be required. Requests for Data Sharing should be directed to information.guardian@phc.ox.ac.uk. Such requests will be considered by all data holders involved in this collaboration. RESEARCH ARTICLE

Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis

Katherine L. Tucker¹, James P. Sheppard¹, Richard Stevens¹, Hayden B. Bosworth², Alfred Bove³, Emma P. Bray⁴, Kenneth Earle⁵, Johnson George⁶, Marshall Godwin⁷, Beverly B. Green⁸, Paul Hebert⁹, F. D. Richard Hobbs¹, Ilkka Kantola¹⁰, Sally M. Kerry¹¹, Alfonso Leiva¹², David J. Magid¹³, Jonathan Mant¹⁴, Karen L. Margolis¹⁵, Brian McKinstry¹⁶, Mary Ann McLaughlin¹⁷, Stefano Omboni¹⁸, Olugbenga Ogedegbe¹⁹, Gianfranco Parati^{20,21}, Nashat Qamar²², Bahman P. Tabaei²³, Juha Varis¹⁰, Willem J. Verberk²⁴, Bonnie J. Wakefield²⁵, Richard J. McManus^{1*}

1 Nuffield Department of Primary Care, University of Oxford, Oxford, United Kingdom, 2 Center for Health Services Research in Primary Care, Durham VAMC, Durham, North Carolina, United States of America, 3 Cardiology, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania, United States of America, 4 School of Psychology, University of Central Lancashire, Preston, United Kingdom, 5 Thomas Addison Diabetes Unit, St. George's NHS Trust, London, United Kingdom, 6 Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Parkville, Australia, 7 Family Medicine, Memorial University of Newfoundland, St. John's, Canada, 8 Kaiser Permanente Washington Health Research Institute, Seattle, Washington, United States of America, 9 Department of Health Services, University of Washington School of Public Health, Seattle, Washington, United States of America, 10 Division of Medicine, Turku University Hospital and University of Turku, Turku, Finland, 11 Centre for Primary Care and Public Health, Queen Mary University of London, London, United Kingdom, 12 Primary Care Research Unit of Mallorca, Baleares Health Services-IbSalut, Mallorca, Spain, 13 Colorado School of Public Health, University of Colorado, Denver, Colorado, United States of America, 14 Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom, 15 HealthPartners Institute for Education and Research, Minneapolis, Minnesota, United States of America, 16 Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom, 17 Icahn School of Medicine at Mount Sinai New York, New York, New York, United States of America, 18 Clinical Research Unit, Italian Institute of Telemedicine, Varese, Italy, 19 Center for Healthful Behavior Change, Division of Health and Behavior, Department of Population Health, Langone School of Medicine, New York University. New York. New York. United States of America. 20 Department of Cardiovascular. Neural and Metabolic Sciences, IRCCS, San Luca Hospital, Istituto Auxologico Italiano, Milan, Italy, 21 Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy, 22 Primary Care Clinical Sciences, University of Birmingham, Birmingham, United Kingdom, 23 Division of Prevention and Primary Care, New York City Department of Health & Mental Hygiene, New York, New York, United States of America, 24 Cardiovascular Research Institute Maastricht and Departments of Internal Medicine, Maastricht University, Maastricht, the Netherlands, 25 Department of Veterans (VA) Health Services Research and Development Centre for Comprehensive Access and Delivery Research and Evaluation (CADRE), Iowa City VA Medical Centre, University of Iowa, Iowa, United States of America

* richard.mcmanus@phc.ox.ac.uk

Abstract

Background

Self-monitoring of blood pressure (BP) appears to reduce BP in hypertension but important questions remain regarding effective implementation and which groups may benefit most. This individual patient data (IPD) meta-analysis was performed to better understand the effectiveness of BP self-monitoring to lower BP and control hypertension.

Funding: This research was funded by the Institute for Health Research School for Primary Care Research (NIHR SPCR number 112) and via an NIHR Professorship for RM (NIHR-RP-02-12-015). JS holds a Medical Research Council (MRC) Strategic Skills Postdoctoral Fellowship (MR/ K022032/1). FDRH is part funded as Director of the National Institute for Health Research (NIHR) School for Primary Care Research (SPCR), Theme Leader of the NIHR Oxford Biomedical Research Centre (BRC), and Director of the NIHR Collaboration for Leadership in Applied Health Research and Care (CLAHRC) Oxford. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing interests: I have read the journal's policy and the authors of this manuscript have the following competing interests: RJM has received research funding in terms of blood pressure monitors from Omron and Lloyds Healthcare; has received expenses and an honorarium from the Japanese Society of Hypertension and American Society of Nephrology. WJV is now employed by Microlife but was not at the time that the data contributed were collected. FDRH has in the past received limited free or subsidised BP measuring devices from Microlife and Omron to support hypertension research where there was no input from the companies to the design, funding, delivery, analysis, or interpretation of that research. SO is a consultant of Biotechmed Ltd. (provider of blood pressure telemonitoring services). SK has received research funding in terms of blood pressure monitors from Omron. HBB has received grant funding to Duke University from Sanofi, Johnson and Johnson, Takeda, WestMeadVaco, and Improved patient Outcome; has received an honorarium from Walgreens, Genentech, Sanofi; and has received funds for consulting for Sanofi. JPS received an MRC Strategic Skills Postdoctoral Fellowship (2013-2016) and now receives funding from the NIHR Oxford Collaborations for Leadership in Applied Health Research and Care. AB owns stocks in Insight Telehealth Systems LLC. MG received a research grant from the Heart and Stroke Foundation of Ontario prior to this work to conduct a study on self-monitoring of blood pressure, data from which are included in this meta-analysis. JG has held unrestricted investigator initiated grants from Pfizer and Boehringer-Ingelheim (BI) for unrelated research: is a member of the Lung Foundation Australia's (LFA) COPD-X guidelines committee. Pfizer, BI, or LFA did not have any role in my decision to participate in the work submitted by Tucker et al. IK has received travel grants and honoraria for

Methods and findings

Medline, Embase, and the Cochrane Library were searched for randomised trials comparing self-monitoring to no self-monitoring in hypertensive patients (June 2016). Two reviewers independently assessed articles for eligibility and the authors of eligible trials were approached requesting IPD. Of 2,846 articles in the initial search, 36 were eligible. IPD were provided from 25 trials, including 1 unpublished study. Data for the primary outcomeschange in mean clinic or ambulatory BP and proportion controlled below target at 12 months -were available from 15/19 possible studies (7,138/8,292 [86%] of randomised participants). Overall, self-monitoring was associated with reduced clinic systolic blood pressure (sBP) compared to usual care at 12 months (-3.2 mmHg, [95% CI -4.9, -1.6 mmHg]). However, this effect was strongly influenced by the intensity of co-intervention ranging from no effect with self-monitoring alone (-1.0 mmHg [-3.3, 1.2]), to a 6.1 mmHg (-9.0, -3.2) reduction when monitoring was combined with intensive support. Self-monitoring was most effective in those with fewer antihypertensive medications and higher baseline sBP up to 170 mmHg. No differences in efficacy were seen by sex or by most comorbidities. Ambulatory BP data at 12 months were available from 4 trials (1,478 patients), which assessed selfmonitoring with little or no co-intervention. There was no association between self-monitoring and either lower clinic or ambulatory sBP in this group (clinic -0.2 mmHg [-2.2, 1.8]; ambulatory 1.1 mmHg [-0.3, 2.5]). Results for diastolic blood pressure (dBP) were similar. The main limitation of this work was that significant heterogeneity remained. This was at least in part due to different inclusion criteria, self-monitoring regimes, and target BPs in included studies.

Conclusions

Self-monitoring alone is not associated with lower BP or better control, but in conjunction with co-interventions (including systematic medication titration by doctors, pharmacists, or patients; education; or lifestyle counselling) leads to clinically significant BP reduction which persists for at least 12 months. The implementation of self-monitoring in hypertension should be accompanied by such co-interventions.

Author summary

Background

- Self-monitoring of BP appears to lower BP in people with hypertension, over and above usual care.
- Implementation of self-monitoring has been inconsistent, perhaps because important evidence gaps remain regarding how best to use it and for which patient groups.

Why was this study done?

• To better understand the effect of self-monitoring on BP lowering and BP control.

speaking or participation at meetings from Sanofi-Genzyme and Shire concerning Fabry disease; has participated in clinical studies concerning diabetic nephropathy and hyperlipidemia sponsored by Bayer, Boehringer-Ingelheim, Merck Sharp and Dome and Pfizer.

Abbreviations: ABPM, ambulatory blood pressure monitoring; BMI, body mass index; BP, blood pressure; CKD, chronic kidney disease; dBP, diastolic blood pressure; DM, diabetes mellitus; IPD, individual patient data; MI, myocardial infarction; RR, relative risk; sBP, systolic blood pressure. • Specifically, to examine the effect of self-monitoring in combination with various cointerventions, and in different groups of patients.

What did the researchers do and find?

- We undertook a systematic literature search to identify all studies that included selfmonitoring of BP in people with high BP.
- For studies published since the year 2000 with at least 6 months of follow-up data and at least 100 patients, we contacted authors to gain access to the original data collected for each individual patient (15/19 studies with the primary outcome provided data: 7,138/ 8,292 randomised participants).
- We then used these data to perform IPD meta-analysis to evaluate the effect of self-monitoring on BP levels and in the control of hypertension using 1 year of follow-up as our primary end point.
- We predefined levels of intensity of co-intervention and subgroups of patients for further analysis.
- Self-monitoring worked best when combined with more intensive interventions such as self-management, systematic medication titration, or lifestyle counselling, but had little or no effect on its own.
- Self-monitoring was most effective in those with fewer antihypertensive medications and higher baseline sBP up to 170 mmHg. No differences in efficacy were seen by sex or by most comorbidities.

What do these findings mean?

- Self-monitoring can be recommended to lower BP when combined with co-interventions involving individually tailored support.
- Self-monitoring alone does not seem to lower BP but may be useful for other reasons including engaging with patients or reducing clinician workload.

Introduction

Treatment of hypertension results in significant reductions in risk of subsequent cardiovascular disease [1,2]. Despite strong evidence for such treatment, international epidemiological studies suggest that many people remain suboptimally controlled [3]. Self-monitoring of blood pressure (BP), where individuals measure their own blood pressure, usually in a home environment, can improve BP control and is an increasingly common part of hypertension management. Such monitoring can be accompanied by additional support such as from a nurse or pharmacist [4]. Self-monitoring is well tolerated by patients and has been shown to be a better predictor of end organ damage than clinic measurement [5-8]. This is despite potential issues with quality control of self-measurement such as poor technique or withholding of results [9,10]. The latter can be reduced to an extent by the use of telemonitoring [11].

Previous meta-analyses have shown that self-monitoring reduces clinic BP by a small but significant amount compared to conventional care (around 4/1.5 mmHg) [4,12–14]. Analysis by Bray and colleagues suggested that when self-monitoring was accompanied by a co-intervention, participants were more likely to meet target BP, but it remains unclear which interventions are most effective and what specific populations (if any) should be targeted [14].

The aim of this work was therefore to use individual patient data (IPD) from relevant trials to assess the effectiveness of BP self-monitoring on BP reduction and hypertension control, evaluating how best to utilise self-monitoring of BP and to determine which subpopulation is most likely to benefit.

Materials and methods

This study systematically reviewed the existing literature to identify randomised trials examining the efficacy of self-monitoring of BP compared to control. Authors of all eligible trials were approached for access to IPD. A protocol with detailed methods has been published previously [15]. The methods used are summarised below.

Data sources and searches

Medline, Embase, and the Cochrane Library were searched for trials using BP self-monitoring in hypertensive patients (S2 Fig; search date June 2016).

Study selection

Two reviewers (RM and KT) independently assessed the articles for eligibility and inclusion; disagreements were resolved by discussion. Randomised trials were eligible that recruited patients with hypertension being managed as outpatients using an intervention that included self-measurement of BP. Self-monitoring had to be without medical professional input (i.e., by patient with or without carer support) and using a validated monitor, with or without other co-interventions, and where a comparator group had no organised self-measurement of BP. Included studies were required to have involved at least 100 patients, followed up for at least 24 weeks, and to have been published since 2000. This was to ensure that self-monitoring equipment was likely to be relevant to contemporary medical management (i.e., automated oscillometric monitors). Relevant outcomes were systolic blood pressure (sBP) and/or diastolic blood pressure (dBP) measured in clinic, by researcher or by ambulatory measurement, and achievement of BP control.

Data extraction and quality assessment

Authors whose trials met the inclusion criteria were approached for provision of IPD including demographic details, comorbidities, antihypertensive medications, lifestyle factors, and BP end points (clinic and/or ambulatory). Study-level data were extracted where available from published articles and checked by the original authors. In particular, any co-interventions were carefully documented and prospectively allocated to 1 of 4 levels of interventional support based on a previous classification [4] (S1 Table).

Study quality was assessed in terms of potential bias from randomisation, blinding, outcome assessment, and method of analysis using an adaptation of the Cochrane tool [16]. Original data were kept on a secure server and assembled in a consistent format for all trials. Three researchers (KT, RM, and JS) cross-checked trial details, summary measures, major outcomes, and definitions against published articles. Any apparent inconsistencies were checked with the original trial authors. Overall ethical approval was not required as this study does not include identifiable data; collaborating groups gained individual approval where required for data sharing.

Data synthesis and analysis

A 2-stage IPD meta-analysis was conducted using linear regression for continuous outcomes and logistic regression for proportions, aggregated across studies by random-effects inverse variance methods. Intention-to-treat comparisons of outcomes between the self-monitoring and comparator arms were summarised with forest plots using the I-squared (I^2) statistic for heterogeneity. Regression models were adjusted for age, sex, baseline clinic BP, and diabetic status (the latter due to the lower BP target generally used in a diabetic population).

The primary outcomes were change in sBP and dBP at 12 months and likelihood of uncontrolled BP below target at 12 months (control as defined by each trial). Analyses are reported in subgroups, by pre-specified level of self-monitoring intervention as described in <u>Table 1</u> and in the published protocol [15].

Subgroup analyses examined the effect of self-monitoring on BP mean and control by age, sex, baseline sBP, the presence and number of antihypertensive medications prescribed, and comorbidities (myocardial infarction [MI], stroke, diabetes mellitus [DM], chronic kidney disease [CKD], and obesity [defined as a body mass index (BMI) \geq 30 kg/m²]). All subgroup analyses were adjusted for age, sex, baseline clinic BP, level of intervention, and individual study (contributing to each analysis).

Sensitivity analyses included incorporation of aggregate data from studies that did not contribute IPD [17–23], exclusion of individual patients for whom a lower home BP target was not used (due to study design or the presence of comorbidities such as diabetes) [24–27], influence of BP inclusion criteria (clinic or ambulatory) from ambulatory outcome studies, different assumptions regarding BP of patients lost to follow-up (controlled or uncontrolled), and influence of adjusting for medication changes (in those studies which recorded changes in medication). Finally, the influence of each study on the overall results was assessed using an influence analysis. Egger's test for funnel plot asymmetry was applied to consider possible publication bias (S21 Fig) [28].

There were no deviations from the protocol [15]. Five post-hoc analyses were undertaken: firstly, an additional subgroup analysis was carried out (resistant hypertension [defined as BP > 140/90 mmHg and 3 medications at baseline or any BP level and 4 or more medications at baseline]); secondly, the distribution of baseline antihypertensive medications was compared in patients with and without a history of stroke using Pearson's chi-squared; thirdly, the effectiveness of self-monitoring in stroke was assessed controlling for the number of baseline medications; fourthly, the influence of blinding was assessed; and finally, sBP was plotted against medication changes.

Statistical software and presentation

All analyses were conducted using STATA version 13.1 (MP parallel edition, StataCorp, College Station, Texas, USA), using the ipdmetan package [29]. Data are presented as proportions of the total study population, means with standard deviation or relative risk (RR) with 95% confidence intervals unless otherwise stated.

HOMER Primary care TASMINH Primary care INNTS Primary care HINTS Primary care HINTS Primary care BP Primary care Outpatients outpatients TCYB Primary care Outpatients Outpatients TeleBPcare Primary care Outpatients Outpatients	< 2 <	readings / session		defined level		target (mmHg)	target (mmHg)	BP ±SD mmHg	randomised	available	W9	12M	18M
TASMINH Primary care HINTS Primary care HINTS Primary care BP Primary care and outpatients TCVB Primary care TCVB Primary care TCVB Primary care Community Outpatients TCVB Primary care Interview Outpatients Care Primary care Interview Outpatients		5	None	-	Usual care	135/80	140/85	157/93 ±18/8	269	231	170	N/A	N/A
HINTS Primary care HOMERUS Primary care BP outpatients eBP and outpatients and TCVB Primary care TCVB Primary care Community care Primary care and Primary care and Primary care and Community care Primary care care Primary care and Primary care primary care	ωĘ	5	None	-	Usual care	140/85 140/80 DM	140/85 140/80 DM	156/88 ±15/7	441	440	413	401	N/A
HOMERUS Primary care and outpatients eBP Primary care and outpatients TCYB Primary care and outpatients Care Care hospital site)	ays per 1 ek	_	Behavioural intervention	e	Usual care	135/85 135/80	140/90 135/80	129/77 ±18/13	593	591	535	523	N/A
HOMERUS Primary care and outpatients eBP Primary care outpatients and outpatients outpatients and outpatients and outpatients and outpatients and outpatients and outpatients and outpatients and outpatients outpatients and outpatients and		1	Or meds management	4		MQ	DM	130/78 ±19/14					
HOMERUS Primary care and outpatients ds, HOMERUS ds, BP and outpatients TCYB Primary care and outpatients TCYB Primary care TeleBPcare Primary care 33 Care 310 Care And Care And Care And Community		1	Or both	4				128/77 ±19/13					
I eBP Primary care and outpatients and outpatients TCYB Primary care brimary care brimary care and outpatients B Care brimary care trimary care brimary care brima	per then 1 fery 2	m	ano	-	Usual care with monthly clinic visits then 2 monthly	140/90	140/90	164/96 ±17/10	517	517	N/A	434	N/A
TCYB Primary care TCYB Primary care TeleBPcare Primary Care Care Care through a hospital site)		2	Website and email	2	Usual care	135/85	140/90	151/89 ±12/9	778	778	N/A	730	N/A
TCYB Primary care TeleBPcare Primary Care Care Care Care Care TeleBPcare Care Care Care Care Care Care Care Community (recruited through a hospital site)		1	+/- web-based pharmacist management	4				151/89 ±12/9					
TeleBPcare Primary 33 33 33 33 33 7 10 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	ays per	_	None	-	Usual care	135/85	140/90	125/71 ±16/10	636 (476 applicable)	446	383	350	324
TeleBPcare Primary 30 010 Care Care Care through a hospital site)			Or behavioural interventions, education, and support	4		130/80 DM	130/80 DM	125/71 ±18/11					
3 010 Primary Care Community (recruited through a hospital site)		2	Telemonitoring	2	Usual care	135/85	140/90	146/88 ±12/8	329	298	298	N/A	N/A
Community (recruited through a hospital site)			None	-	Usual care	135/85	140/90	144/81 ±18/11	552	458	458	458	N/A
	ekly	_	Blood glucose testing, text/app system with feedback from clinicians	4	Usual care	140/90	140/90	131/77 ±17/10	137	126	126	N/A	N/A
McManus I ASMINH2 Primary care Daily to [36] first wer UK, 2010 each m	Daily for the first week of each month	2	Telemonitoring and self- titration	ю	Usual care	130/85 130/75 DM	140/90 140/80 DM	152/85 ±12/9	527	527	480	480	N/A
Hebert [40] Outpatients Variable US, 2011 and primary		Not clear	None	-	Usual care		140/90	153/86 16/13	416	416	N/A	N/A	286
care			Or nurse support	4			130/ 80DM	153/86 18/13					

Table 1. Characteristics of the included studies.

Lead author (s) [Ref] Country, Year	Study	Setting	Self- monitoring	Number of readings / session	Co-interventions	Pre- defined level	Comparison	Home target (mmHg)	Clinic target (mmHg)	Baseline BP ±SD mmHg	No. randomised	Data available	No. 6M	No. 12M	No. 18M
Wakefield [31] US, 2011		Primary care	Daily	-	Low-intensity management algorithm	2	Usual care	135/85	135/85	135/72 ±18/11	302	300	268	261*	N/A
					High-intensity algorithm	e		130/80 DM	130/80 DM	136/74 ±19/11					
Bove [44] US, 2013	HTN	Primary care and outpatients	2 days per week	Not clear	Telemonitoring	2	Usual care		140/90	155/88 ±15/11	241	235	202	N/A	N/A
Kerry [39] UK, 2013		Community (recruited from stroke services)	Daily in week 1, then 1 day per week	ε	Nurse-led telephone support	2	Usual care	130/80	140/85	138/74 ±21/12	381	381	352	334	N/A
Magid [50] US, 2013		Primary care	3 days per week	÷	Patient education and BP reporting; or patient education, BP reporting, and pharmacist management	4	Usual care	135/85 125/75 DM/CKD	140/90 130/80 DM/ CKD	147/15 ±89/10	338	326	326	A/A	A/N
Margolis [<u>37]</u> US, 2013	Hyperlink	Primary care	3 days per week	2	Telemonitoring and pharmacist management	4	Usual care	135/85 125/75 DM/CKD	140/90 130/80 DM/CKD	148/85 ±13/12	450	450	403	388	370
McKinstry [45] UK, 2013	НПЗ	Primary care	Daily in week 1, then at least 1 day per week thereafter	5	Optional automated telemonitoring	5	Usual care	135/85	140/90	153/91 ±15/11	401	401	374	N/A	N/A
Parati [<u>32]</u> Italy, 2013	TeleBPMET	Primary care	3 days per week	2	Telemonitoring	2	Usual care	135/85	140/90	147/90 ±12/8	252	182	181	179	N/A
Green [51] US, 2014	eCare		At least 1 day per week for 2 months, then 1 day per fortnight for 2 months, then monthly	2	Dietician with BP plan and visits (weekly for 2 months, fortnightly for 2 months, then monthly)	4	Usual care	135/85	140/90	±12/9 ±12/9	101	101	06	A/N	A/N
Leiva [46] Spain, 2014	Adherencia	Primary care	Weekly, with morning and afternoon readings	ę	Motivational interview, pilbox reminder, family support, BP and medication reminder form, and pharmacist review	n	Usual care	135/85	140/90 and 130/ 80 for DM or CKD	±15/11 ±15/11	221	215	N/A	215	A/N
McManus [35] UK 2014	TASMIN-SR	Primary care	Daily for the first week of each month	2	Self-management	ĸ	Usual care	120/75	130/80 ST	144/80 ±13/10	552	450	439	450	N/A
Ogedegbe [34] US, 2014	СААТСН	Primary care	3 days per week		Education, lifestyle, and behavioural support	e	Usual care			151/91 ±17/10	1,039	997	610	691	N/A
													<u> </u>	(Continued)	(pənu

Self-monitoring of BP in hypertension (BP-SMART)

Table 1. (Continued)

Lead author (s) [Ref] Country, Year	Study	Setting	Self- monitoring	Number of readings / session	Co-interventions	Pre- defined level	Comparison	Home target (mmHg)	Clinic target (mmHg)	Baseline BP ±SD mmHg	No. randomised	Data available	No. 6M	12M 1	No. 18M
Stewart [48] Australia, 2014	НАРРу	Primary care	Several readings per week	-	Pharmacist management with motivational interviewing, education review, education, and optional refill reminders	4	Usual care	140/90 and 130/ 80 for DM and CKD	140/90 and 130/ 80 for DM and CKD	141/84 ±20/11	395	391	351	N/A A	N/A
Yi [47] US, 2015		Primary care	Primary care As prescribed by their doctor	Variable	Educational material on hypertension	-	Usual care	140/90 or 130/ 80 DM or CKD	140/90 or 130/ 80 DM or CKD	152/83 ±16/11	006	828	529	A/N	N/A
Parati (unpublished study) Italy	AUPRES	Primary care 3 days per week	3 days per week	ო		-	Usual care	135/85	140/90	154/95 ±15/8	407	407	407	407	407
Summary info	rmation of in	cluded studies	s. Differences t	oetween nu	Summary information of included studies. Differences between number randomised and data available for Godwin (2010) and McManus (2014) are due to the use of complete case	ind data a	tvailable for Go	odwin (201	0) and Mc	Manus (20 ⁻	14) are due to	the use of	comp	ete cas	e

data only. The difference observed in Bosworth (2009) results from the removal of the behavioural intervention arm and patients with missing baseline BP data. Abbreviations: BP, blood pressure; CKD, chronic kidney disease; DM, diabetes mellitus; GP, general practitioner; M, months; ST, self-tested BP. *Participants self-monitored for 6 months; follow-up data collected at 12 months.

https://doi.org/10.1371/journal.pmed.1002389.t001

Table 1. (Continued)

Results

Of 2,846 unique studies from the combined searches, 132 were assessed in full and 36 studies were deemed potentially eligible (S1 Fig). One study which would otherwise have been eligible was excluded because the comparator group used ambulatory monitoring to guide treatment, a control intervention that had not been anticipated in the protocol but which was not comparable to any other included studies [30]. Of the 36 potentially eligible studies, 19 had published data at 12 months, the primary outcome. Authors from 24 of the potentially eligible studies provided IPD, with 1 group submitting additional data from an unpublished study. These 25 studies were published from 2005–2014, were conducted in North America and Europe (11 United States; 6 United Kingdom; 3 Italy; 1 each from the Netherlands, Australia, Spain, Finland, and Canada), and included a wide range of self-monitoring protocols, co-interventions, and populations (Table 1) [23-27,31-48]. Authors from the remaining 12 studies were either unable to provide IPD (2 studies) or did not respond to the request for data (10 studies). Four studies which followed up patients for 12 months did not provide IPD, so that data for the primary outcome were available from 15/19 studies (7,138/8,292 [86%], of potential participants) (S2 Table) [17,18,22,49]. A total of 838 patients (12%) were lost to follow-up across all included studies, and a further 227 patients from the potentially available studies were lost to follow-up, leaving 6,300/7,227 patients (87%) for inclusion in the final analysis of the primary outcome (12 months follow-up).

Overall, the information from the included trials was judged to be at low risk of bias: most studies used computerised generation of randomisation sequences (23/25, 92%), appropriate allocation concealment (24/25, 96%), and all used an intention-to-treat approach with either multiple imputation for missing data or analysis of complete cases. Most studies (19/25, 76%) followed up more than 80% of participants, but only 12/25 (48%) used blinded assessment of outcome (S3 Table). An influence analysis assessed the impact of each individual study on the overall results. Included studies were predominantly publically funded (S4 Table).

Clinic BP

Overall, self-monitoring was associated with reduced clinic sBP between baseline and 12-months follow-up compared to usual care (systolic -3.2 mmHg, 95% CI -4.9 to -1.6 mmHg) (Fig 1). Significant heterogeneity was present between studies: $I^2 = 76\%$, P < 0.001. Self-monitoring was also associated with reduced dBP at 12-months follow-up (diastolic -1.5 mmHg, 95% CI -2.2 to -0.8 mmHg) and significant heterogeneity remained ($I^2 = 62\%$, P < 0.001) (Fig 2). Similar reductions in BP were seen after 6-months follow-up, but the point estimates after 18-months follow-up were smaller, albeit from only 5 studies (S3, S4, S6 and S7 Figs).

Clinic BP control

Clinic BP control was improved at 12-months follow-up (RR of uncontrolled BP 0.7 [95% CI 0.56 to 0.86]) again with significant heterogeneity between groups (Fig 3). Similar results were seen at 6 and 18 months (<u>S5</u> and <u>S8</u> Figs, respectively).

Intensity of co-intervention

The reductions in clinic sBP varied with different levels of intervention: level 1 (with no cointervention) –1.0 mmHg, [95% CI –3.3 to 1.2 mmHg]; level 4 (personal support throughout the trial) –6.1 mmHg, [95% CI –9.0 to –3.2 mmHg] (Fig 1) (heterogeneity in outcome between

Intervention and Study	Total populatio	on Contro	I Intervention		% Weigł
Self-monitoring with	n no fee	dback			
TASMINH1	401	212	189	-1.21 (-4.16, 1.75)	5.3
Godwin et al.,	458	209	249	-1.93 (-4.69, 0.83)	5.5
HOMERUS	434	208	226	2.51 (-0.46, 5.47)	5.3
AUPRES	407	210	197	0.10 (-2.20, 2.40)	5.
TCYB - Con vs. Int 1	234	122	112	-5.59 (-9.46, -1.72)	4.
Subtotal	1934	961	973	-1.02 (-3.27, 1.23)	26.
(I-squared = 66.6%, p =	0.018)				
Self-monitoring with	n web/pl	hone fee	edback		
TeleBPMet	179	57	122	-1.88 (-5.86, 2.09)	4.0
Kerry et al.,	334	167	167	0.04 (-3.86, 3.93)	4.
eBP - Con vs. Int 1	493	247	246	-2.88 (-5.51, -0.24)	5.
Wakefield - Con vs. Int 1	183	102	81	-2.16 (-6.70, 2.39)	4.:
Subtotal	1189	573	616	-1.98 (-3.74, -0.21)	19.:
(I-squared = 0.0%, p = 0	.687)				
СААТСН	691	366	325	-0.71 (-3.88, 2.46)	5.
Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int 2 Subtotal	214 264 2 180 2279	366 103 137 102 1184	325 111 127 78 1095	-0.71 (-3.88, 2.46) -2.42 (-6.61, 1.78) -2.27 (-6.60, 2.05) -6.36 (-10.97, -1.75) -4.42 (-7.11, -1.73)	4. 4. 4.
CAATCH Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int 2 Subtotal (I-squared = 69.3%, p = Self-monitoring with	214 264 2 180 2279 0.006)	103 137 102 1184	111 127 78 1095	-2.42 (-6.61, 1.78) -2.27 (-6.60, 2.05) -6.36 (-10.97, -1.75) -4.42 (-7.11, -1.73)	4.4 4.4 4.2
Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int 2 Subtotal (I-squared = 69.3%, p =	214 264 2 180 2279 0.006)	103 137 102 1184	111 127 78 1095	-2.42 (-6.61, 1.78) -2.27 (-6.60, 2.05) -6.36 (-10.97, -1.75) -4.42 (-7.11, -1.73)	5.: 4.! 4.: 29.0
Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int 2 Subtotal (I-squared = 69.3%, p = Self-monitoring with	214 264 2 180 2279 0.006)	103 137 102 1184 elling/te	111 127 78 1095 Iecounselling	-2.42 (-6.61, 1.78) -2.27 (-6.60, 2.05) -6.36 (-10.97, -1.75) -4.42 (-7.11, -1.73)	4.4 4.4 29.0
Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int 2 Subtotal (I-squared = 69.3%, p = Self-monitoring with Hyperlink	214 264 2 180 2279 0.006) n <u>couns</u> 388	103 137 102 1184 elling/te	111 127 78 1095 Iecounselling 197	-2.42 (-6.61, 1.78) -2.27 (-6.60, 2.05) -6.36 (-10.97, -1.75) -4.42 (-7.11, -1.73) -9.24 (-12.15, -6.33)	4.4 4.4 29.0
Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int 2 Subtotal (I-squared = 69.3%, p = Self-monitoring with Hyperlink TCYB - Con vs. Int 2	214 264 2 180 2279 0.006) 1 couns 388 238	103 137 102 1184 elling/te 191 122	111 127 78 1095 Iecounselling 197 116	-2.42 (-6.61, 1.78) -2.27 (-6.60, 2.05) -6.36 (-10.97, -1.75) -4.42 (-7.11, -1.73) -9.24 (-12.15, -6.33) -3.00 (-6.74, 0.74)	4.4 4.2 29.0 5.4 4.3
Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int 2 Subtotal (I-squared = 69.3%, p = Self-monitoring with Hyperlink TCYB - Con vs. Int 2 HINTS - Con vs. Int 2	214 264 2180 2279 0.006) 1 couns 388 238 269	103 137 102 1184 elling/te 191 122 137	111 127 78 1095 lecounselling 197 116 132 127 237	-2.42 (-6.61, 1.78) -2.27 (-6.60, 2.05) -6.36 (-10.97, -1.75) -4.42 (-7.11, -1.73) -9.24 (-12.15, -6.33) -3.00 (-6.74, 0.74) -2.79 (-7.21, 1.64)	4.4 4.2 29.0 5.4 4.4 4.4
Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int 2 Subtotal (I-squared = 69.3%, p = Self-monitoring with Hyperlink TCYB - Con vs. Int 2 HINTS - Con vs. Int 2 HINTS - Con vs. Int 3	214 264 2180 2279 0.006) 1 couns 388 238 269 264	103 137 102 1184 elling/te 191 122 137 137	111 127 78 1095 lecounselling 197 116 132 127	-2.42 (-6.61, 1.78) -2.27 (-6.60, 2.05) -6.36 (-10.97, -1.75) -4.42 (-7.11, -1.73) -9.24 (-12.15, -6.33) -3.00 (-6.74, 0.74) -2.79 (-7.21, 1.64) -5.20 (-9.41, -1.00)	4.4 4.4 29.0 5.4 4.4 4.4 5.0
Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int 2 Subtotal (I-squared = 69.3%, p = Self-monitoring with Hyperlink TCYB - Con vs. Int 2 HINTS - Con vs. Int 2 HINTS - Con vs. Int 3 eBP - Con vs. Int 2	214 264 2180 2279 0.006) a couns 388 238 269 264 484 1506	103 137 102 1184 elling/tei 191 122 137 137 247	111 127 78 1095 lecounselling 197 116 132 127 237	-2.42 (-6.61, 1.78) -2.27 (-6.60, 2.05) -6.36 (-10.97, -1.75) -4.42 (-7.11, -1.73) -9.24 (-12.15, -6.33) -3.00 (-6.74, 0.74) -2.79 (-7.21, 1.64) -5.20 (-9.41, -1.00) -8.75 (-11.36, -6.14)	4.4 4.2 29.0 5.4
Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int 2 Subtotal (I-squared = 69.3%, p = Self-monitoring with Hyperlink TCYB - Con vs. Int 2 HINTS - Con vs. Int 2 HINTS - Con vs. Int 3 eBP - Con vs. Int 2 Subtotal	214 264 2 180 2279 0.006) a couns 388 238 269 264 484 1506 0.014)	103 137 102 1184 elling/te 191 122 137 137 247 697	111 127 78 1095 lecounselling 197 116 132 127 237	-2.42 (-6.61, 1.78) -2.27 (-6.60, 2.05) -6.36 (-10.97, -1.75) -4.42 (-7.11, -1.73) -9.24 (-12.15, -6.33) -3.00 (-6.74, 0.74) -2.79 (-7.21, 1.64) -5.20 (-9.41, -1.00) -8.75 (-11.36, -6.14)	4.4 4.4 29.0 5.4 4.4 4.4 5.0
Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int 2 Subtotal (I-squared = 69.3%, p = Self-monitoring with Hyperlink TCYB - Con vs. Int 2 HINTS - Con vs. Int 2 HINTS - Con vs. Int 3 eBP - Con vs. Int 2 Subtotal (I-squared = 68.2%, p =	214 264 2 180 2279 0.006) a couns 388 238 269 264 484 1506 0.014)	103 137 102 1184 elling/te 191 122 137 137 247 697	111 127 78 1095 lecounselling 197 116 132 127 237	-2.42 (-6.61, 1.78) -2.27 (-6.60, 2.05) -6.36 (-10.97, -1.75) -4.42 (-7.11, -1.73) -9.24 (-12.15, -6.33) -3.00 (-6.74, 0.74) -2.79 (-7.21, 1.64) -5.20 (-9.41, -1.00) -8.75 (-11.36, -6.14)	4.: 4.: 29.0 5.: 4.: 4.: 4.: 5.0 24.0
Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int 2 Subtotal (I-squared = 69.3%, p = Self-monitoring with Hyperlink TCYB - Con vs. Int 2 HINTS - Con vs. Int 2 HINTS - Con vs. Int 3 eBP - Con vs. Int 2 Subtotal (I-squared = 68.2%, p =	214 264 2 180 2279 0.006) 1 couns 388 238 269 264 484 1506 0.014) groups: Pr 6300	103 137 102 1184 elling/te 191 122 137 137 247 697	111 127 78 1095 lecounselling 197 116 132 127 237 809	-2.42 (-6.61, 1.78) -2.27 (-6.60, 2.05) -6.36 (-10.97, -1.75) -4.42 (-7.11, -1.73) -9.24 (-12.15, -6.33) -3.00 (-6.74, 0.74) -2.79 (-7.21, 1.64) -5.20 (-9.41, -1.00) -8.75 (-11.36, -6.14) -6.10 (-9.02, -3.18)	4. 4. 29. 5. 4. 4. 4. 5. 24.
Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int 2 Subtotal (I-squared = 69.3%, p = Self-monitoring with Hyperlink TCYB - Con vs. Int 2 HINTS - Con vs. Int 2 HINTS - Con vs. Int 3 eBP - Con vs. Int 2 Subtotal (I-squared = 68.2%, p = Heterogeneity between g Overall	214 264 2 180 2279 0.006) 1 couns 388 238 269 264 484 1506 0.014) groups: Pr 6300	103 137 102 1184 elling/te 191 122 137 137 247 697	111 127 78 1095 lecounselling 197 116 132 127 237 809	-2.42 (-6.61, 1.78) -2.27 (-6.60, 2.05) -6.36 (-10.97, -1.75) -4.42 (-7.11, -1.73) -9.24 (-12.15, -6.33) -3.00 (-6.74, 0.74) -2.79 (-7.21, 1.64) -5.20 (-9.41, -1.00) -8.75 (-11.36, -6.14) -6.10 (-9.02, -3.18)	4.: 4.: 29.0 5.: 4.: 4.: 4.: 5.0 24.0

Fig 1. Impact of self-monitoring of BP on clinic sBP according to level of co-intervention support at 12 months (15 studies). Change in sBP adjusted for age, sex, baseline clinic BP, and history of diabetes. The trials are grouped into the 4 levels of intervention, and P^2 and P values are shown for each level of intervention and for the overall analysis. Effect of self-monitoring on clinic sBP at 6 and 18 months are shown in S3 and S6 Figs, respectively. Wakefield's study participants self-monitored for 6 months; follow-up continued to 12 months. Abbreviations: BP, blood pressure; sBP, systolic blood pressure.

Intervention and Study	Total population	Control	Intervention	Mean dBP diff (95% Cl)	% W
Self-monitoring wit	h no feedk	back			
TASMINH1	401	212	189	-0.96 (-2.52, 0.60)	
Godwin et al.,	458	209	249	-1.94 (-3.57, -0.31)	
HOMERUS	434	208	226	1.08 (-0.57, 2.72)	
AUPRES	407	210	197	-0.80 (-2.31, 0.70)	
TCYB - Con vs. Int 1	234	122	112	-3.27 (-5.40, -1.14)	
Subtotal	1934	961	973	-1.10 (-2.39, 0.19)	2
(I-squared = 66.2%, p =				\sim	
Calf manitoning with	h		dh e e le		
Self-monitoring wit					
TeleBPMet	179	57	122	0.54 (-2.19, 3.26)	
Kerry et al.,	334	167	167		
eBP - Con vs. Int 1	493	247	246	-0.47 (-1.91, 0.97)	
Wakefield - Con vs. Int		102	81	-1.51 (-4.31, 1.29)	
Subtotal (I-squared = 0.0%, p = 0	1189	573	616	-0.46 (-1.47, 0.56)	1
TASMINH2	480	246	234	-2.51 (-4.03, -0.99)	
TASMINH2	480	246	234	-2.51 (-4.03, -0.99)	
TASMINH-SR	450	230	220	-3.20 (-4.62, -1.78)	
CAATCH	691	366	325	-0.57 (-2.28, 1.14)	
	214	103	111	-0.97 (-3.27, 1.32)	
Leiva et al.,	214				
Leiva et al., HINTS - Con vs. Int 1	264	137	127	-0.84 (-3.32, 1.63)	
,	264	137 102	127 78	-0.84 (-3.32, 1.63) -2.58 (-5.34, 0.19)	
HINTS - Con vs. Int 1	264				
HINTS - Con vs. Int 1 Wakefield - Con vs. Int	264 2 180 2279	102	78	-2.58 (-5.34, 0.19)	
HINTS - Con vs. Int 1 Wakefield - Con vs. Int Subtotal (I-squared = 34.4%, p = Self-monitoring wit	264 2 180 2279 ■ 0.178) h counsel	102 1184 ling/tele	78 1095 ecounsellir	-2.58 (-5.34, 0.19) -1.91 (-2.87, -0.94) g	2
HINTS - Con vs. Int 1 Wakefield - Con vs. Int Subtotal (I-squared = 34.4%, p = Self-monitoring wit Hyperlink	264 2 180 2279 • 0.178) h counsel 388	102 1184 ling/tela 191	78 1095 ecounsellir 197	g -2.58 (-5.34, 0.19) -1.91 (-2.87, -0.94) -4.89 (-6.69, -3.09)	2
HINTS - Con vs. Int 1 Wakefield - Con vs. Int Subtotal (I-squared = 34.4%, p = Self-monitoring wit	264 2 180 2279 ■ 0.178) h counsel	102 1184 ling/tele	78 1095 ecounsellir	-2.58 (-5.34, 0.19) -1.91 (-2.87, -0.94) g	2
HINTS - Con vs. Int 1 Wakefield - Con vs. Int Subtotal (I-squared = 34.4%, p = Self-monitoring wit Hyperlink TCYB - Con vs. Int 2 HINTS - Con vs. Int 2	264 2 180 2279 • 0.178) h counsel 388 238 238 269	102 1184 ling/tele 191 122 137	78 1095 ecounsellir 197 116 132	g -2.58 (-5.34, 0.19) -1.91 (-2.87, -0.94) -1.91 (-2.87, -0.94) -1.00 (-3.07, 1.07) -0.68 (-3.14, 1.77)	2
HINTS - Con vs. Int 1 Wakefield - Con vs. Int Subtotal (I-squared = 34.4%, p = Self-monitoring wit Hyperlink TCYB - Con vs. Int 2 HINTS - Con vs. Int 2 HINTS - Con vs. Int 3	264 2 180 2279 • 0.178) h counsell 388 238 269 264	102 1184 ling/teld 191 122 137 137	78 1095 ecounsellir 197 116 132 127	g -2.58 (-5.34, 0.19) -1.91 (-2.87, -0.94) -1.91 (-2.87, -0.94) -4.89 (-6.69, -3.09) -1.00 (-3.07, 1.07) -0.68 (-3.14, 1.77) -0.75 (-3.30, 1.81)	2
HINTS - Con vs. Int 1 Wakefield - Con vs. Int Subtotal (I-squared = 34.4%, p = Self-monitoring wit Hyperlink TCYB - Con vs. Int 2 HINTS - Con vs. Int 2	264 2 180 2279 • 0.178) h counsel 388 238 238 269	102 1184 ling/tele 191 122 137	78 1095 ecounsellir 197 116 132	g -2.58 (-5.34, 0.19) -1.91 (-2.87, -0.94) -1.91 (-2.87, -0.94) -1.00 (-3.07, 1.07) -0.68 (-3.14, 1.77)	2
HINTS - Con vs. Int 1 Wakefield - Con vs. Int Subtotal (I-squared = 34.4%, p = Self-monitoring wit Hyperlink TCYB - Con vs. Int 2 HINTS - Con vs. Int 2 HINTS - Con vs. Int 3	264 2 180 2279 • 0.178) h counsell 388 238 269 264	102 1184 ling/teld 191 122 137 137	78 1095 ecounsellir 197 116 132 127	g -2.58 (-5.34, 0.19) -1.91 (-2.87, -0.94) -1.91 (-2.87, -0.94) -4.89 (-6.69, -3.09) -1.00 (-3.07, 1.07) -0.68 (-3.14, 1.77) -0.75 (-3.30, 1.81)	2
HINTS - Con vs. Int 1 Wakefield - Con vs. Int Subtotal (I-squared = 34.4%, p = Self-monitoring wit Hyperlink TCYB - Con vs. Int 2 HINTS - Con vs. Int 2 HINTS - Con vs. Int 3 eBP - Con vs. Int 2	264 2 180 2279 0.178) h counsell 388 238 269 264 484 1506	102 1184 ling/tela 191 122 137 137 247	78 1095 ecounsellir 197 116 132 127 237	g -2.58 (-5.34, 0.19) -1.91 (-2.87, -0.94) -1.91 (-2.87, -0.94) -1.00 (-3.07, 1.07) -0.68 (-3.14, 1.77) -0.75 (-3.30, 1.81) -3.35 (-4.85, -1.84)	2
HINTS - Con vs. Int 1 Wakefield - Con vs. Int Subtotal (I-squared = 34.4%, p = Self-monitoring wit Hyperlink TCYB - Con vs. Int 2 HINTS - Con vs. Int 2 HINTS - Con vs. Int 3 eBP - Con vs. Int 2 Subtotal	264 2 180 2279 c 0.178) h counsell 388 238 269 264 484 1506 c 0.011)	102 1184 ling/teld 191 122 137 137 247 697	78 1095 ecounsellir 197 116 132 127 237	g -2.58 (-5.34, 0.19) -1.91 (-2.87, -0.94) -1.91 (-2.87, -0.94) -1.00 (-3.07, 1.07) -0.68 (-3.14, 1.77) -0.75 (-3.30, 1.81) -3.35 (-4.85, -1.84)	2
HINTS - Con vs. Int 1 Wakefield - Con vs. Int Subtotal (I-squared = 34.4%, p = Self-monitoring wit Hyperlink TCYB - Con vs. Int 2 HINTS - Con vs. Int 2 HINTS - Con vs. Int 3 eBP - Con vs. Int 2 Subtotal (I-squared = 69.1%, p =	264 2 180 2279 c 0.178) h counsell 388 238 269 264 484 1506 c 0.011)	102 1184 ling/teld 191 122 137 137 247 697	78 1095 ecounsellir 197 116 132 127 237	g -2.58 (-5.34, 0.19) -1.91 (-2.87, -0.94) -1.91 (-2.87, -0.94) -1.00 (-3.07, 1.07) -0.68 (-3.14, 1.77) -0.75 (-3.30, 1.81) -3.35 (-4.85, -1.84)	2
HINTS - Con vs. Int 1 Wakefield - Con vs. Int Subtotal (I-squared = 34.4%, p = Self-monitoring wit Hyperlink TCYB - Con vs. Int 2 HINTS - Con vs. Int 2 HINTS - Con vs. Int 3 eBP - Con vs. Int 2 Subtotal (I-squared = 69.1%, p =	264 2 180 2279 c 0.178) h counsell 388 238 269 264 484 1506 c 0.011) groups: p = 6300	102 1184 191 122 137 137 247 697	78 1095 ecounsellir 197 116 132 127 237 809	g 4.89 (-6.69, -3.09) -1.91 (-2.87, -0.94) -1.91 (-2.87, -0.94) -1.00 (-3.07, 1.07) -0.68 (-3.14, 1.77) -0.75 (-3.30, 1.81) -3.35 (-4.85, -1.84) -2.32 (-4.04, -0.59)	2
HINTS - Con vs. Int 1 Wakefield - Con vs. Int Subtotal (I-squared = 34.4%, p = Self-monitoring wit Hyperlink TCYB - Con vs. Int 2 HINTS - Con vs. Int 2 HINTS - Con vs. Int 3 eBP - Con vs. Int 2 Subtotal (I-squared = 69.1%, p = Heterogeneity between Overall	264 2 180 2279 c 0.178) h counsell 388 238 269 264 484 1506 c 0.011) groups: p = 6300	102 1184 191 122 137 137 247 697	78 1095 ecounsellir 197 116 132 127 237 809	g 4.89 (-6.69, -3.09) -1.91 (-2.87, -0.94) -1.91 (-2.87, -0.94) -1.00 (-3.07, 1.07) -0.68 (-3.14, 1.77) -0.75 (-3.30, 1.81) -3.35 (-4.85, -1.84) -2.32 (-4.04, -0.59)	2

Fig 2. Impact of self-monitoring of BP on clinic dBP according to level of co-intervention support at 12 months (15 studies). Change in dBP adjusted for age, sex, baseline clinic BP, and history of diabetes. The trials are grouped into the 4 levels of intervention, and P and P values are shown for each level of intervention and for the overall analysis. Effect of self-monitoring on clinic dBP at 6 and 18 months are shown in S4 and S7 Figs, respectively. Wakefield's participants self-monitored for 6 months; follow-up continued to 12 months. Abbreviations: BP, blood pressure; dBP, diastolic blood pressure.

Intervention and Study	Total populatic	n Control	I Intervention	RR of uncontrolled BP (95% Cl)	9 9 V
Self-monitoring witl	h no food	hack			
TASMINH1	401	212	189	0.95 (0.60, 1.52)	
Godwin et al.,	458	209	249	0.85 (0.57, 1.28)	
HOMERUS	434	203	226	1.33 (0.90, 1.96)	
AUPRES	407	200	197		
TCYB - Con vs. Int 1	234	122	112	0.42 (0.19, 0.93)	
Subtotal	1934	961	973	0.99 (0.72, 1.37)	
(I-squared = 56.0%, p =	= 0.059)				
Self-monitoring with	h web/ph	one feed	back		
TeleBPMet	179	57	122	0.83 (0.38, 1.78)	
Kerry et al.,	334	167	167	1.06 (0.66, 1.70)	
eBP - Con vs. Int 1	493	247	246	0.77 (0.53, 1.13)	
Wakefield - Con vs. Int	1 183	102	81	1.07 (0.56, 2.04)	
Subtotal	1189	573	616	0.90 (0.69, 1.15)	
(I-squared = 0.0%, p = 0	0.713)				
TAOMUNILOD		230	220	0.37 (0.25, 0.55)	
TASMINH-SR	450				
CAATCH	691	366	325	0.79 (0.57, 1.10)	
CAATCH Leiva et al.,	691 214	366 103	325 111	0.79 (0.57, 1.10) 0.46 (0.23, 0.94)	
CAATCH Leiva et al., HINTS - Con vs. Int 1	691 214 264	366 103 137	325 111 127	0.79 (0.57, 1.10) 0.46 (0.23, 0.94) 0.67 (0.38, 1.16)	
CAATCH Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int	691 214 264 2 180	366 103 137 102	325 111 127 78	0.79 (0.57, 1.10) 0.46 (0.23, 0.94)	
CAATCH Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int Subtotal	691 214 264 2 180 2279	366 103 137	325 111 127	0.79 (0.57, 1.10) 0.46 (0.23, 0.94) 0.67 (0.38, 1.16)	
CAATCH Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int	691 214 264 2 180 2279	366 103 137 102	325 111 127 78	0.79 (0.57, 1.10) 0.46 (0.23, 0.94) 0.67 (0.38, 1.16) 0.61 (0.31, 1.19)	
CAATCH Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int Subtotal	691 214 264 2 180 2279 = 0.104)	366 103 137 102 1184	325 111 127 78 1095	0.79 (0.57, 1.10) 0.46 (0.23, 0.94) 0.67 (0.38, 1.16) 0.61 (0.31, 1.19)	
CAATCH Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int Subtotal (I-squared = 45.2%, p =	691 214 264 2 180 2279 = 0.104)	366 103 137 102 1184	325 111 127 78 1095	0.79 (0.57, 1.10) 0.46 (0.23, 0.94) 0.67 (0.38, 1.16) 0.61 (0.31, 1.19)	
CAATCH Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int Subtotal (I-squared = 45.2%, p = Self-monitoring with	691 214 264 2 180 2279 = 0.104) h counsel	366 103 137 102 1184	325 111 127 78 1095 counselling	0.79 (0.57, 1.10) 0.46 (0.23, 0.94) 0.67 (0.38, 1.16) 0.61 (0.31, 1.19) 0.57 (0.44, 0.73)	
CAATCH Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int Subtotal (I-squared = 45.2%, p = Self-monitoring with Hyperlink	691 214 264 2 180 2279 = 0.104) h counsel 388	366 103 137 102 1184 Iling/teleo	325 111 127 78 1095 counselling 197	0.79 (0.57, 1.10) 0.46 (0.23, 0.94) 0.67 (0.38, 1.16) 0.61 (0.31, 1.19) 0.57 (0.44, 0.73) 0.35 (0.22, 0.56)	
CAATCH Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int Subtotal (I-squared = 45.2%, p = Self-monitoring witt Hyperlink TCYB - Con vs. Int 2	691 214 264 2 180 2279 = 0.104) h counsel 388 238	366 103 137 102 1184 Iling/telet 191 122	325 111 127 78 1095 counselling 197 116	0.79 (0.57, 1.10) 0.46 (0.23, 0.94) 0.67 (0.38, 1.16) 0.61 (0.31, 1.19) 0.57 (0.44, 0.73) 0.35 (0.22, 0.56) 0.72 (0.34, 1.53)	
CAATCH Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int Subtotal (I-squared = 45.2%, p = Self-monitoring with Hyperlink TCYB - Con vs. Int 2 HINTS - Con vs. Int 2	691 214 264 2 180 2279 = 0.104) h counsel 388 238 269	366 103 137 102 1184 Iling/teleo 191 122 137	325 111 127 78 1095 counselling 197 116 132	0.79 (0.57, 1.10) 0.46 (0.23, 0.94) 0.67 (0.38, 1.16) 0.61 (0.31, 1.19) 0.57 (0.44, 0.73) 0.55 (0.22, 0.56) 0.72 (0.34, 1.53) 0.56 (0.32, 0.99)	
CAATCH Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int Subtotal (I-squared = 45.2%, p = Self-monitoring with Hyperlink TCYB - Con vs. Int 2 HINTS - Con vs. Int 2 HINTS - Con vs. Int 3	691 214 264 2 180 2279 = 0.104) h counsel 388 238 269 264	366 103 137 102 1184 Iling/teleo 191 122 137 137	325 111 127 78 1095 counselling 197 116 132 127	0.79 (0.57, 1.10) 0.46 (0.23, 0.94) 0.67 (0.38, 1.16) 0.61 (0.31, 1.19) 0.57 (0.44, 0.73) 0.57 (0.44, 0.73) 0.55 (0.22, 0.56) 0.72 (0.34, 1.53) 0.56 (0.32, 0.99) 0.60 (0.33, 1.06)	
CAATCH Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int Subtotal (I-squared = 45.2%, p = Self-monitoring with Hyperlink TCYB - Con vs. Int 2 HINTS - Con vs. Int 2 HINTS - Con vs. Int 3 eBP - Con vs. Int 2	691 214 264 2 180 2279 = 0.104) h counsel 388 238 269 264 484 1506	366 103 137 102 1184 Iling/telee 191 122 137 137 247	325 111 127 78 1095 counselling 197 116 132 127 237	0.79 (0.57, 1.10) 0.46 (0.23, 0.94) 0.67 (0.38, 1.16) 0.61 (0.31, 1.19) 0.57 (0.44, 0.73) 0.57 (0.44, 0.73) 0.56 (0.32, 0.99) 0.60 (0.33, 1.06) 0.37 (0.25, 0.53)	
CAATCH Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int Subtotal (I-squared = 45.2%, p = Self-monitoring with Hyperlink TCYB - Con vs. Int 2 HINTS - Con vs. Int 2 HINTS - Con vs. Int 3 eBP - Con vs. Int 2 Subtotal	691 214 264 2 180 2279 = 0.104) h counsel 388 238 269 264 484 1506 = 0.337)	366 103 137 102 1184 Iling/teleo 191 122 137 137 247 697	325 111 127 78 1095 counselling 197 116 132 127 237	0.79 (0.57, 1.10) 0.46 (0.23, 0.94) 0.67 (0.38, 1.16) 0.61 (0.31, 1.19) 0.57 (0.44, 0.73) 0.57 (0.44, 0.73) 0.56 (0.32, 0.99) 0.60 (0.33, 1.06) 0.37 (0.25, 0.53)	
CAATCH Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int Subtotal (I-squared = 45.2%, p = Self-monitoring with Hyperlink TCYB - Con vs. Int 2 HINTS - Con vs. Int 2 HINTS - Con vs. Int 3 eBP - Con vs. Int 2 Subtotal (I-squared = 12.0%, p =	691 214 264 2 180 2279 = 0.104) h counsel 388 238 269 264 484 1506 = 0.337)	366 103 137 102 1184 Iling/teleo 191 122 137 137 247 697	325 111 127 78 1095 counselling 197 116 132 127 237	0.79 (0.57, 1.10) 0.46 (0.23, 0.94) 0.67 (0.38, 1.16) 0.61 (0.31, 1.19) 0.57 (0.44, 0.73) 0.57 (0.44, 0.73) 0.56 (0.32, 0.99) 0.60 (0.33, 1.06) 0.37 (0.25, 0.53)	1
CAATCH Leiva et al., HINTS - Con vs. Int 1 Wakefield - Con vs. Int Subtotal (I-squared = 45.2%, p = Self-monitoring with Hyperlink TCYB - Con vs. Int 2 HINTS - Con vs. Int 2 HINTS - Con vs. Int 2 HINTS - Con vs. Int 3 eBP - Con vs. Int 2 Subtotal (I-squared = 12.0%, p = Heterogeneity between	691 214 264 2 180 2279 = 0.104) h counsel 388 238 269 264 484 1506 = 0.337) groups: P < 6300	366 103 137 102 1184 lling/teleo 191 122 137 137 247 697	325 111 127 78 1095 counselling 197 116 132 127 237 809	0.79 (0.57, 1.10) 0.46 (0.23, 0.94) 0.67 (0.38, 1.16) 0.61 (0.31, 1.19) 0.57 (0.44, 0.73) 0.55 (0.22, 0.56) 0.72 (0.34, 1.53) 0.56 (0.32, 0.99) 0.60 (0.33, 1.06) 0.37 (0.25, 0.53) 0.44 (0.34, 0.57)	

Fig 3. Impact of self-monitoring of BP on the RR of uncontrolled BP at 12 months according to level of co-intervention support (15 studies). RR of uncontrolled BP adjusted for age, sex, baseline clinic BP, and history of diabetes. The trials are grouped into the 4 levels of intervention, and \hat{P} and P values are shown for each level of intervention and for the overall analysis. The effect of self-monitoring on the RR of BP at 6 and 18 months are displayed in S5 and S8 Figs, respectively. Wakefield study participants self-monitored for 6 months; follow-up continued to 12 months. Abbreviations: BP, blood pressure; RR, relative risk.

different levels of intervention P < 0.001). Within predefined categories of intensity of cointervention, significant heterogeneity remained, apart from within level 2.

A similar pattern of reductions was seen in dBP: level 1 (with no co-intervention) -1.1 mmHg, [95% CI -2.4 to 0.2 mmHg]; level 4 (personal support throughout the trial) -2.3 mmHg, [95% CI -4.0 to -0.6 mmHg] (Fig 2) (heterogeneity in outcome between different levels of intervention P < 0.001). Within predefined categories of intensity of co-intervention, significant heterogeneity remained in levels 1 and 4.

BP control (defined according to individual study targets, Table 1) at 12 months also differed by level of intensity. The RR of having uncontrolled BP with a self-monitoring intervention at 12 months varied from level 1 (RR 1.0, 95% CI 0.7 to 1.4) to level 4 (RR 0.4, 95% CI 0.3 to 0.6) (Fig 3) (heterogeneity between levels of intervention P < 0.001). Heterogeneity within levels of intervention in this analysis was low for levels 2 and 4 of co-intervention, although the I^2 remained above 50% for level 1. Similar results were seen at 6-months follow-up (21 studies) and at 18-months follow-up (5 studies) (S5 and S8 Figs, respectively).

Ambulatory BP

Four studies had data at 12 months using ambulatory BP as the outcome (1,478 participants); these were studies with no co-intervention (level 1; n = 3) or automated feedback only (level 2; n = 1). No change was seen in ambulatory sBP associated with self-monitoring (1.1 mmHg [-0.3, 2.5]) (Fig 4) or ambulatory dBP (0.8 mmHg [-0.2, 1.9]), and there was no significant heterogeneity between studies in either case (Fig 5). At 6 months, data were available for 5 studies with no difference seen in ambulatory sBP (-1.0 mmHg [-2.8, 0.9]) or dBP (-0.4 mmHg [-1.6, 0.8]) (S9 and S10 Figs, respectively). The additional study, which used a level 3--intensity intervention, increased heterogeneity as it had a significant outcome.

No ambulatory data were available at 18 months.

Subgroup analysis

Subgroup analyses using data from 12-months follow-up showed little difference in either reduction of systolic or diastolic clinic BP or likelihood of uncontrolled BP depending on history of MI or presence of CKD or diabetes (Figs 6, 7 and 8) ($I^2 \leq 20\%$ for all subgroups).

However, a history of stroke was associated with a reduced effectiveness of self-monitoring in terms of clinic sBP lowering ($I^2 = 77\%$, P = 0.04), though this difference was not observed for dBP or maintained in the likelihood of control analysis (RR $I^2 = 42\%$, P = 0.19). Post-hoc analyses showed that the distribution of number of medications between stroke and nonstroke patients was similar (S5 Table), and adjusting for baseline medication use did not explain the lack of effectiveness in patients with stroke. There was moderate heterogeneity between age groups for the effect of self-monitoring on systolic and diastolic clinic BP ($I^2 =$ 31%, P = 0.20 and $I^2 = 33$, P = 0.19, respectively) but not in the likelihood of uncontrolled BP ($I^2 = 0.0\%$, P = 0.60). Considering the effect of obesity, there was no difference in the effect on systolic clinic BP reduction ($I^2 = 0$, P = 0.72) but there was some evidence of heterogeneity of effect for dBP ($I^2 = 63$, P = 0.10) and the risk of uncontrolled BP ($I^2 = 61\%$, P = 0.11).

Fewer baseline antihypertensive medications were associated with larger reductions of BP and better control (Figs 6–8). Post-hoc analyses, comparing those with resistant hypertension to those without, suggested that self-monitoring was less effective at achieving BP control in the former (RR of uncontrolled BP = 0.62, 95% CI 0.54–0.71 [non-resistant hypertension] versus RR of uncontrolled BP = 0.94, 95% CI 0.65–1.36 [resistant hypertension], $I^2 = 76\%$, P = 0.04). Similarly, the post-hoc analysis plotting change in sBP against medication changes






Fig 4. Impact of self-monitoring of BP on clinic and ambulatory sBP at 12 months (4 studies). These 4 studies used both clinic and ambulatory BP as endpoints and so are presented in addition to the overall results in Fig 1, which are for clinic BP alone (including these studies). Change in sBP adjusted for age, sex, baseline clinic BP, history of diabetes, and level of intervention. Effect of self-monitoring on systolic clinic and ambulatory BP at 6 months is in S9 Fig. Abbreviations: BP, blood pressure; sBP, systolic blood pressure.

https://doi.org/10.1371/journal.pmed.1002389.g004

BP measurement	Total							N	lean dBP diff	%
and Study	population	Control	Intervention					(!	95% CI)	Weigh
nic blood pressu	ire (I-square	ed = 58.6°	%, p=0.064)							
Godwin et al.,	458	209	249			•		-	1.94 (-3.57, -0.31)	27.40
HOMERUS	434	208	226			_		1	.08 (-0.57, 2.72)	27.2
TeleBPMet	179	57	122					0	.54 (-2.19, 3.26)	16.4
AUPRES	407	210	197					-(0.80 (-2.31, 0.70)	28.9
Subtotal	1478	684	794			\langle	>	-(0.38 (-1.78, 1.01)	100.0
bulatory blood			d = 32.9%, p=0.215)							
Godwin et al.,	458	209	249			•		-(0.21 (-1.56, 1.14)	33.7
HOMERUS	434	208	226					1	.92 (0.21, 3.62)	25.3
TeleBPMet	179	57	122				*	- 1	.90 (-0.81, 4.62)	12.5
AUPRES	407	210	197					0	.58 (-0.99, 2.14)	28.3
Subtotal	1478	684	794			<	\bigcirc	0	.82 (-0.23, 1.87)	100.0
			-1(n	 5	(5		

NOTE: Weights are from Random-effects; DerSimonian-Laird estimator

Fig 5. Impact of self-monitoring of BP on clinic and ambulatory dBP at 12 months (4 studies). These 4 studies used both clinic and ambulatory BP as endpoints and so are presented in addition to the overall results in Fig 1, which are for clinic BP alone (including these studies). Change in dBP adjusted for age, sex, baseline clinic BP, history of diabetes, and level of intervention. Effect of self-monitoring on diastolic clinic and ambulatory BP at 6 months is in S10 Fig. Abbreviations: BP, blood pressure; dBP, diastolic blood pressure.

Sub-group and category	Total studie	Total s population	on Contro	Intervention		Mean sBP diff (95% CI)	% Weig
Age (I-squar	ed = 31	.3%, p=0.2	01)				
< 40 years	12	134	62	72	·	-3.65 (-8.39, 1.09)	4.5
40-49 years	15	680	320	360		-4.19 (-6.47, -1.91)	15.5
50-59 years	15	1640	696	944		-1.96 (-3.54, -0.39)	
60-69 years	15	2045	872	1173	×	-4.55 (-6.00, -3.09)	
70-79 years	15	1367	644	723		-2.34 (-4.19, -0.48)	
≥ 80 years	13	434	213	221		-3.78 (-7.47, -0.09)	7.1
Sex (I-sa	uared =	: 0.0%, p=0	.888)				
Female	15	2470	1135	1335	· · · · · · · · · · · · · · · · · · ·	-3.40 (-4.72, -2.09)	39.1
Male	15	3830	1672	2158	÷	-3.28 (-4.34, -2.23)	60.8
Baseline sB	P (-squared =	52.4%, p	=0.78)			
< 140 mmHg	15	1961	799	1162		-2.28 (-3.70, -0.87)	26.6
140-149 mmHg	15	1818	845	973	·	-4.20 (-5.66, -2.73)	26.0
150-159 mmHg	15	1158	531	627		-3.68 (-5.53, -1.83)	21.5
160-169 mmHg	15	716	337	379	• • • • • • • • • • • • • • • • • • •	-5.37 (-8.10, -2.65)	13.9
≥ 170 mmHg	15	647	295	352		-0.76 (-3.84, 2.31)	11.8
Baseline me	dicat	ions (I	-squared =	= 62.3%, p=0.04)		
No medication	9	244	117	127	•	-7.49 (-11.00, -3.99)) 15.0
1 drug	10	1518	687	831	—	-4.51 (-6.09, -2.92)	30.6
2 drugs	10	1566	727	839	<u> </u>	-4.45 (-6.13, -2.78)	29.7
3 or more drugs	10	1134	448	686	· •	-1.85 (-4.06, 0.35)	24.5
History of M	I	(I-square	d = 0.0%,	p=0.379)			
No MI	9	4036	2031	2005	• • ·	-4.20 (-5.20, -3.21)	96.6
MI	8	239	123	116		-1.77 (-7.11, 3.58)	3.3
History of s	roke	(I-so	quared = 7	7.4%, p=0.036)			
No Stroke	9	3692	1730	1962		-4.44 (-5.48, -3.39)	59.0
Stroke	9	561	285	276	×	-0.87 (-4.03, 2.28)	40.9
	(I-squared =	= 0.0%, p=	0.513)			
Diabetes	14	4722	2100	2622		-3.01 (-3.93, -2.08)	78.8
		45 45	690	855		-3.68 (-5.47, -1.89)	21.1
No Diabetes	14	1545					
No Diabetes Diabetes	14	1545 quared = 0.0	0%, p=0.4	12)			
No Diabetes Diabetes CKD	14		0%, p=0.4 1614	12) 1906	÷	-3.97 (-5.05, -2.90)	946
No Diabetes Diabetes CKD No CKD	14 (I-so	quared = 0.0			+	-3.97 (-5.05, -2.90) -5.91 (-10.42, -1.41)	
No Diabetes Diabetes CKD No CKD CKD	14 (I-so 9 8	quared = 0.0 3520	1614 164	1906	÷		
No Diabetes Diabetes CKD No CKD CKD Obesity (I-s	14 (I-so 9 8	quared = 0.0 3520 307	1614 164	1906	÷) 5.3
No Diabetes Diabetes CKD No CKD CKD Obesity (I-s Not obese	14 (I-so 9 8 squarec	uared = 0.0 3520 307 I = 0.0%, p=	1614 164 =0.715)	1906 143	÷ ÷	-5.91 (-10.42, -1.41)) 5.3 55.2
Diabetes No Diabetes Diabetes CKD No CKD CKD Obesity (I-s Not obese Obese	14 (I-so 9 8 squarec 15	quared = 0.0 3520 307 I = 0.0%, p= 3133	1614 164 =0.715) 1441	1906 143 1692	÷	-5.91 (-10.42, -1.41) -2.89 (-4.04, -1.74)) 5.3 55.2

Fig 6. Impact of self-monitoring of BP on clinic sBP at 12 months according to prespecified subgroups (15 studies). Obesity defined as $BMI \ge 30 \text{ kg/m}^2$. Change in sBP at 12 months adjusted for age, sex, baseline clinic BP, level of intervention, and studies contributing patient data. Abbreviations: BMI, body mass index; BP, blood pressure; CKD, chronic kidney disease; MI, myocardial infarction; sBP, systolic blood pressure.

Sub-group and category		Total populati	ion Contro	I Intervention		Mean dBP diff (95% Cl)
Age (I-squa	ared = 33.	4%, p=0.1	186)			
< 40 years	12	134	62	72	_	-4.17 (-7.37, -0.98
40-49 years	15	680	320	360		-2.27 (-3.74, -0.80
50-59 years	15	1640	696	944		-0.60 (-1.50, 0.30)
60-69 years	15	2045	872	1173		-1.59 (-2.37, -0.81
70-79 years	15	1367	644	723		-1.35 (-2.34, -0.36
≥ 80 years	13	434	213	221		-1.48 (-3.39, 0.44)
Sex (I-s	quared =	50.1% n=	=0 157)			
Female	15	2470	1135	1335		-1.09 (-1.81, -0.38
Male	15	3830	1672	2158	+	-1.77 (-2.36, -1.17
Baseline sl	3P (I-s	auared =	0.0%, p=0	.708)	Ť	
< 140 mmHg	15	1961	799	1162		-1.37 (-2.19, -0.54
140-149 mmH		1818	845	973		-1.66 (-2.49, -0.83
150-159 mmH	-	1158	531	627		-1.54 (-2.58, -0.50
160-169 mmH	-	716	337	379		-1.77 (-3.18, -0.36
≥ 170 mmHg	15	647	295	352	*	-0.45 (-1.98, 1.09)
Deselling	1141			07.404 - 0.00		
Baseline m		244 (1-squared =	= 67.4%, p=0.02 127		-3.97 (-6.08, -1.87
1 drug	10	1518	687	831	•	-2.20 (-3.10, -1.30
2 drugs	10	1566	727	839		-1.71 (-2.62, -0.80
3 or more drug	js 10	1134	448	686	· · · ·	-0.55 (-1.73, 0.64)
History of I	MI	(I-square	ed = 28.2%	. p=0.238)		
No MI	9	4036	2031	2005	•	-1.88 (-2.43, -1.33
MI	8	239	123	116		-0.31 (-2.86, 2.24)
History of s	stroke	(I-s	quared = 2	1.3%, p=0.260)		
No Stroke	9	3692	1730	1962	•	-1.87 (-2.44, -1.30
Stroke	9	561	285	276		-0.85 (-2.53, 0.83)
Diabetes	(1	-squared	= 0.0%, p=	0.715)		
No Diabetes	14	4722	2100	2622	•	-1.54 (-2.06, -1.02
Diabetes	14	1545	690	855	*	-1.33 (-2.30, -0.37
СКД	(I-sqi	uared = 0.	.0%, p=0.6 ⁻	12)		
No CKD	9	3520	1614	1906	•	-1.69 (-2.29, -1.10
	8	307	164	143		-2.29 (-4.54, -0.05
CKD			n=0.098)			
	-squared	= 63.4%.	p 0.000)			
	-squared 15	= 63.4%, 3133	1441	1692	—	-1.77 (-2.411.13
Obesity (I				1692 1511	*	-1.77 (-2.41, -1.13 -0.96 (-1.68, -0.24
Obesity (I Not obese	15	3133	1441		*	

Fig 7. Impact of self-monitoring of BP on clinic dBP at 12 months according to prespecified subgroups (15 studies). Obesity defined as $BMI \ge 30 \text{ kg/m}^2$. Change in dBP at 12 months adjusted for age, sex, baseline clinic BP, level of intervention, and studies contributing patient data. Abbreviations: BMI, body mass index; BP, blood pressure; CKD, chronic kidney disease; dBP, diastolic blood pressure; MI, myocardial infarction.

Sub-group and category	Total studies	Total population	Control	Intervention	RR of uncontroller BP (95% CI)	d % Weig
Age (I-squar	ed = 0.0%	6, p=0.595)				
< 40 years	12	134	62	72	• 0.44 (0.18, 1.08)	1.5
40-49 years	15	680	320	360	0.68 (0.48, 0.96)	10.5
50-59 years	15	1640	696	944	0.81 (0.65, 1.00)	26.6
60-69 years	15	2045	872	1173	0.64 (0.53, 0.78)	33.1
70-79 years	15	1367	644	723	0.74 (0.58, 0.94)	21.6
≥ 80 years	13	434	213	221	0.71 (0.45, 1.10)	6.3
Sex (I-so	quared =	0.0%, p=0.66	69)			
Female	15	2470	1135	1335	0.72 (0.61, 0.86)	39.1
Male	15	3830	1672	2158	0.69 (0.60, 0.79)	60.8
Baseline sBP	(I-square	d = 38.2%, p	=0.166)			
< 140 mmHg	15	1961	799	1162	0.77 (0.63, 0.95)	25.7
140-149 mmHg	15	1818	845	973	0.64 (0.52, 0.78)	26.4
150-159 mmHg	15	1158	531	627	0.68 (0.53, 0.88)	20.5
160-169 mmHg	15	716	337	379	0.57 (0.41, 0.79)	14.4
≥170 mmHg	15	647	295	352	0.97 (0.68, 1.39)	12.7
Baseline med	ications	(I-squared =	= 73.3%,	p=0.011)		
No medication	9	244	117	127	0.33 (0.18, 0.61)	13.3
1 drug	10	1518	687	831	0.60 (0.48, 0.75)	29.3
2 drugs	10	1566	727	839	0.63 (0.50, 0.78)	29.8
3 or more drugs	10	1134	448	686	0.90 (0.69, 1.17)	27.4
History of M	l (I-squa	ared = 0.0%,	p=0.346)			
No MI	9	4036	2031	2005	0.64 (0.56, 0.73)	94.6
MI	8	239	123	116	0.84 (0.48, 1.48)	5.3
History of st	roke (I	-squared = 4	2.3%, p=	0.188)		
No Stroke	9	3692	1730	1962	0.63 (0.55, 0.72)	71.4
Stroke	9	561	285	276	0.82 (0.57, 1.19)	28.5
Diabetes	(I-square	ed = 0.0%, p=	=0.828)			
No Diabetes	14	4722	2100	2622	0.70 (0.62, 0.80)	74.3
Diabetes	14	1545	690	855	0.72 (0.58, 0.90)	25.6
CKD (I-s	quared =	0.0%, p=0.4	21)			
No CKD	9	3520	1614	1906	0.64 (0.56, 0.74)	92.3
CKD	8	307	164	143	0.52 (0.32, 0.86)	7.6
Obesity (I-squ	ared = 60).9%, p=0.11	0)			
Not obese	15	3133	1441	1692	0.79 (0.68, 0.92)	51.8
Obese	15	2590	1079	1511	0.65 (0.55, 0.77)	48.
					I	
					.5 1 1.5	
					Favours intervention Favours control	

Fig 8. Impact of self-monitoring of BP on the RR of uncontrolled BP at 12 months according to prespecified subgroups (15 studies). Obesity defined as $BMI \ge 30 \text{ kg/m}^2$. RR of uncontrolled BP at 12 months adjusted for age, sex, baseline clinic BP, level of intervention, and studies contributing patient data. Abbreviations: BMI, body mass index; BP, blood pressure; CKD, chronic kidney disease; MI, myocardial infarction; RR, risk ratio; sBP, systolic blood pressure.

was consistent with the hypothesis that self-monitoring interventions resulted in BP decreases via increases in prescribed medication (S22 Fig).

Sensitivity analysis

Inclusion of aggregate data for clinic BP at 12 months from the 4 eligible studies that did not contribute IPD (S2 Table) and exclusion of studies that did not use a lower home BP threshold did not materially change the results (S11 and S12 Figs). The exclusion of studies that randomised on the basis of ambulatory BP monitoring (ABPM) or studies that randomised on clinic BP did not change the impact of clinic or ambulatory measurement of sBP at 12 months (S13 and S14 Figs). Assuming patients lost to follow-up had uncontrolled BP attenuated the results, whereas assuming that they had controlled BP accentuated them (S15 and S16 Figs, respectively). Exclusion of patients with controlled BP at baseline also accentuated the results (S17 Fig). A post-hoc comparison of studies with blinded outcome (2,829 patients) versus unblinded (3,257 patients) showed that blinding was associated with a reduced point estimate for the change in sBP at 12 months in those studies examining higher-level interventions, albeit with overlapping confidence intervals (level 1 & 2 intervention studies: -1.51, 95% CI -4.06 to 1.04 [blinded] versus -0.83, 95% CI -2.38 to 0.73 [unblinded]; level 3 & 4 intervention studies: -4.67, 95% CI -7.51 to -1.84 [blinded] versus -6.16, 95% CI -9.36 to -2.95 [unblinded]).

Where studies had measured changes in antihypertensive medication over time, there was evidence of attenuation of the change in sBP when the analysis was adjusted for change in medication (S18 and S19 Figs). The influence analysis did not suggest that any one study was materially influencing the results (S20 Fig and Egger's test found no evidence of asymmetry in the funnel plot (P = 0.9, S21 Fig).

Discussion

Main findings

Using IPD from 25 studies totalling 10,487 patients, this meta-analysis provides strong evidence that the degree of BP lowering is related to the intensity of the co-intervention (i.e., additional support) combined with self-monitoring, with little or no effect from self-monitoring alone.

These results held whether systolic or diastolic clinic BP or clinic BP control were assessed and were consistent at both 6 and 12 months. No data were available from studies with intensive co-interventions which used ambulatory BP monitoring to measure outcomes at 12 months or longer, and those with little or no co-intervention showed similar effects to the clinic BP data (no effect in either case). There was a suspicion of attenuation of the effect of self-monitoring in the few studies to date that have followed up patients for longer than 1 year but data were sparse. Future research might be directed towards longer studies with ambulatory BP measurement (or other measurements to reduce the white coat effect) for outcomes. Self-monitoring appeared most effective at lowering BP in people on fewer BP medications at baseline, and there was a suggestion of a greater effect with higher BP-provided BP was not 170 mmHg or above. Analyses considering those with apparent resistant hypertension at baseline suggested that self-monitoring works less well in this group, but this analysis was not prespecified, could not take into account dose of antihypertensive medication, and should be interpreted with caution. In terms of comorbidities, the effects of self-monitoring were similar whether or not an individual had a history of MI, diabetes, or CKD. In people with previous stroke, there may be a reduced effect of self-monitoring but this did not reflect more intensive treatment prior to randomisation.

Strengths and weaknesses

To our knowledge, this is the first analysis of self-monitoring of BP to use IPD from a wide range of self-monitoring trials from North America, Australia, and Europe and including both specialist and primary care settings. IPD allowed for standardised adjustment of outcomes and sufficient power to detect differences between subgroups.

An important issue in IPD analysis is selection of studies. The BP—SMART collaboration has gained access to a large number of datasets; nevertheless, some studies were not available due to unavailability of data or lack of response. Despite this, only 4 studies eligible for the primary outcome (14% of available patient data) were unable to provide data, and sensitivity analyses suggested no material change in the results when the published aggregate data from these studies were included.

Quality of included studies was adequate in terms of randomisation sequences, appropriate allocation concealment, and analyses. Follow-up was high for most studies but only half used blinded assessment of outcome. However, a post-hoc sensitivity analysis showed no difference in results from blinding, perhaps because in most studies BP was assessed using automated monitors reducing the chance of bias.

Despite the use of IPD and the division of studies into subgroups, significant heterogeneity remained, which limited the ability to do meta-analysis. However, this does not negate the conclusion that the evidence for both BP reduction and control is stronger for higher-intensity interventions and weak for self-monitoring alone. The hypothesis that effect would vary with level of intervention was prespecified and the categorisation of studies into 4 levels of intervention was agreed to by all study investigators before results were available.

Whilst all included studies compared self-monitoring of BP to control groups without selfmonitoring, inevitably different investigators used different protocols and therefore studies differed in inclusion criteria, self-monitoring regime, and target BPs. These issues could at least in part explain the remaining heterogeneity between studies. The exclusion of studies which did not use lower BP targets for self-monitored BP did not change the results, but even IPD analysis is unable to take differences between studies entirely into account and this may be reflected in the heterogeneity which remained. Significance tests should be interpreted with caution when, as in Figs 6 and 7, multiple coequal exposures are under test; however, the 3 *P* values \leq 5% for heterogeneity across these 18 tests are unlikely to be all due to chance alone and the tests were prespecified.

Most outcome data were based on clinic measurement of BP, which is what was used by the majority of trials of outcome of hypertension treatment [1]. Ambulatory monitoring might reduce any attenuation to the white coat effect from repeated habituation to measurement but, whilst 6 studies used ambulatory BP as an outcome [25,32,33,43,45] (including 1 unpublished study), all but 1 of these used less intensive or no co-interventions. The single intensive study with an ambulatory outcome had data to 6 months and a positive result, whereas the remaining 4 studies showed no impact on ambulatory BP in common with the pooled results for clinic BP. Other studies have used multiple automated BP measurements in the clinic to assess habituation and have found no evidence that the BP differences are removed when the white coat effect is reduced, though further studies examining the effects of self-monitoring with intensive co-interventions on outcomes which reduce white coat effects are arguably needed [36] [35].

Even with IPD, issues such as loss to follow-up may be important. Included studies had rates of follow-up between 58% and 98% at 12 months with most studies following-up around 90%. In the main analysis, formal methods for handling missing data were not used since methods for imputation in IPD meta-analysis are in their infancy; however, the impact of each

individual study on the overall results as assessed by the influence analysis suggests that factors such as differential follow-up between studies were unlikely to have affected the results [52].

The outcomes included in this review are all related to BP. Whilst BP is directly related to stroke and coronary heart disease risk, it is nevertheless an intermediate outcome. Ideally, such hard outcomes would be directly measured in trials. However, because of relatively short follow-up and small numbers of participants, few included individual trials did so.

Comparison with the previous literature

There have been previous systematic reviews of trials of self-monitoring [4,13,14,53], including those focussing on specific outcomes such as adherence [54] or processes such as telemonitoring [55], but all previous analyses have relied on summary statistics rather than IPD. Compared to the most recent and comprehensive summary data review, the current study has provided pooled estimates of the effect of self-monitoring with different levels of co-intervention, suggests that self-monitoring alone has little impact on BP, and provides new evidence that the level of BP reduction is related to the intensity of the co-intervention [4].

Self-monitoring in the absence of such a co-intervention had little effect on BP. This is not to say that self-monitoring alone should be discouraged, for it brings other advantages both theoretical (better estimation of the underlying BP, increased self-efficacy for the patient) [6] and practical (increased adherence, reduced need for monitoring within the clinic, and identification of white coat and masked hypertension) [24,54]. These advantages are despite any potential inaccuracy caused by individuals not conforming to the recommended self-monitoring regime [9,10].

Obese patients had similar BP reductions to non-obese individuals but greater chance of BP control, which does not reflect differences in mean BP. The findings concerning patients with previous stroke and resistant hypertension require some caution, particularly the latter which was a post-hoc analysis, but have not been previously described. In the case of stroke, the results do not appear to be due to baseline intensity of antihypertensive treatment and warrant further study as more data become available.

Meaning of the study

Combining self-monitoring with increased collaboration between patient and either a nurse, physician, or pharmacist can result in important decreases in BP (6 mmHg systolic on average for the more intensive co-interventions) and improved control. The mechanisms for these reductions in BP could include lifestyle changes (no data available); increased adherence to medication (no data available) [54]; or increased prescription of medications, i.e., overcoming clinical inertia (data available from 11 studies). In order to assess the impact of enhanced medication prescription, number of medication changes was plotted against changes in BP and showed that increased numbers of medication changes were weakly correlated with reduced BP (S22 Fig). Whatever the mechanism, the literature suggests that a 6 mmHg reduction in sBP, as observed in higher-intensity interventions, would reduce subsequent stroke by more than 20% [56]. Considering the content of such interventions is an important part of decisionmaking in the implementation of self-monitoring. Table 1 and S1 Table describe the key characteristics of effective interventions which depend on actively intervening in terms of medication titration and/or health behaviours. Much of the effect appears to be associated with oneto-one intervention combined with medication intensification. Self-monitoring can therefore facilitate significant improvements in BP level and control but should not necessarily be seen as reducing clinical input because clinical input within the co-interventions is often required for effective BP lowering.

The recent SPRINT trial results suggest that more intensive BP interventions are likely to be important in terms of morbidity and mortality [57]. Increasing the level or intensity of intervention also increases the cost of an intervention, both directly to the health provider and also in terms of patients' time. Understanding the relative cost-effectiveness of the different co-interventions is likely to be important in deciding policy in this area and will require further work.

The effects appear to be independent of age, sex, and a range of comorbidities (such as MI, CKD, diabetes, and obesity), but there was a suggestion that people receiving less intensive antihypertensive treatment, and those with the highest BPs (up to 170 mmHg systolic), may have the most to gain, presumably because they are not already receiving sufficient doses of medication. Conversely, with resistant hypertension there appeared to be little effect from self-monitoring. Similar results for stroke should be interpreted cautiously and warrant further study.

The data presented appear to indicate a potential attenuation of the beneficial effects of selfmonitoring over time (see <u>S6</u>, <u>S7</u> and <u>S8</u> Figs). We believe that the key issue is a need for longer studies (at least 2 years, and preferably 5 years or more) that are accompanied by investigation of how best to administer a self-monitoring—based intervention in the long term, including whether it should be perhaps "topped up" with additional training over time.

Finally, we know from the individual trials that only a proportion of those with hypertension will be suitable for self-monitoring. Despite this, the numbers of people with hypertension and access to their own BP monitor are likely to be well into the tens of millions internationally and represent an important population to engage with [58,59].

Future research

Several unanswered questions remain. Ultimately, trials including cardiovascular endpoints would provide the strongest evidence for self-monitoring in the management of hypertension but may not be appropriate given the strong evidence linking BP to outcome. Further consideration of self-monitoring in the presence of comorbidities seems warranted, particularly for stroke. Furthermore, this review has not included economic outcomes (available from 6 of the included studies) or quality of life measures (available in 8 of the included studies), and these outcomes form part of the next series of investigations for this collaboration.

Conclusions

Self-monitoring of BP combined with co-interventions involving individually tailored support lowers clinic BP but has little effect on its own. Self-monitoring supported by such co-interventions should be recommended as part of routine clinical practice in international guidelines and further research should determine the most cost-effective means of supporting implementation.

Supporting information

S1 PRISMA Checklist. PRISMA checklist. (DOC)

S1 Text. The protocol paper published by the BMJ Open (available at <u>http://bmjopen.bmj.</u> com/content/bmjopen/5/9/e008532.full.pdf). (PDF)

S1 Table. Levels of self-monitoring intervention. Levels used to describe the included self-monitoring interventions. * 1:1 contact or support in this context refers to contact over and

above that in usual care. Abbreviation: BP, blood pressure. (DOCX)

S2 Table. Studies not included in the IPD analysis. *Data were available from trials including 7,138/8,292 (86%) of patients randomised. ⁺Data at 6 months follow-up were available from 8,563/12,822 (67%) of patients randomised. Abbreviation: IPD, individual patient data. (DOCX)

S3 Table. Assessment of bias. *Due to the nature of the intervention, the participants in all studies were aware that they were in the self-monitoring group. (DOCX)

S4 Table. Funding provided to the included studies. Table showing the funding of the included studies.

(DOCX)

S5 Table. Distribution of baseline medications by history of stroke. (DOCX)

S1 Fig. Flow diagram of the systematic search and selection of relevant studies. Flow diagram of the systematic review and selection of studies for the IPD. (DOCX)

S2 Fig. Example search strategy. An example search from Medline. (DOCX)

S3 Fig. Impact of self-monitoring of BP on clinic sBP according to level of co-intervention support at 6 months (21 studies). Change in sBP adjusted for age, sex, baseline clinic BP, and history of diabetes. Abbreviations: BP, blood pressure; sBP, systolic blood pressure. (TIF)

S4 Fig. Impact of self-monitoring of BP on clinic dBP according to level of co-intervention support at 6 months (21 studies). Change in dBP adjusted for age, sex, baseline clinic BP, and history of diabetes. Abbreviations: BP, blood pressure; dBP, diastolic blood pressure. (TIF)

S5 Fig. Impact of self-monitoring of BP on the RR of uncontrolled BP at 6 months according to level of co-intervention support (21 studies). RR of uncontrolled BP adjusted for age, sex, baseline clinic BP, and history of diabetes. Abbreviations: BP, blood pressure; RR, relative risk.

(TIF)

S6 Fig. Impact of self-monitoring of BP on clinic sBP according to level of co-intervention support at 18 months (5 studies). Change in sBP adjusted for age, sex, baseline clinic BP, and history of diabetes. Abbreviations: BP, blood pressure; sBP, systolic blood pressure. (TIF)

S7 Fig. Impact of self-monitoring of BP on clinic dBP according to level of co-intervention support at 18 months (5 studies). Change in dBP adjusted for age, sex, baseline clinic BP, and history of diabetes. Abbreviations: BP, blood pressure; dBP, diastolic blood pressure. (TIF)

S8 Fig. Impact of self-monitoring of BP on the RR of uncontrolled BP at 18 months according to level of co-intervention support (5 studies). RR of uncontrolled BP adjusted for age, sex, baseline clinic BP, and history of diabetes. Abbreviations: BP, blood pressure; RR, relative risk. (TIF)

S9 Fig. Impact of self-monitoring of BP on clinic and ambulatory sBP at 6 months. Change in sBP adjusted for age, sex, baseline clinic BP, history of diabetes, and level of intervention. Abbreviations: BP, blood pressure; sBP, systolic blood pressure. (TIF)

S10 Fig. Impact of self-monitoring of BP on clinic and ambulatory dBP at 6 months. Change in dBP adjusted for age, sex, baseline clinic BP, history of diabetes, and level of intervention. Abbreviations: BP, blood pressure; dBP, diastolic blood pressure. (TIF)

S11 Fig. Change in sBP at 12 months including aggregate data from studies which did not contribute IPD for the primary analysis (19 studies). *Four studies containing aggregate data only: Varis et al. [17], Rinfret et al. [22], Artinian et al. [18], and Kim et al. [49]. Change in sBP from studies contributing IPD adjusted for age, sex, baseline clinic BP, and history of diabetes. Abbreviations: IPD, individual patient data; sBP, systolic blood pressure. (TIF)

S12 Fig. Primary analyses excluding all studies* which did not use a home BP threshold which was lower than clinic BP. Change in sBP at 12 months. *Patients from TASMINH1 (Verberk et al. [25] and McManus et al. [24]) and diabetics from HINTS (Bosworth et al. [26]) and TCYB (Bosworth et al. [27]) all excluded. Change in sBP adjusted for age, sex, baseline clinic BP, and history of diabetes. Abbreviations: BP, blood pressure; sBP, systolic blood pressure.

(TIF)

S13 Fig. Primary analyses (ABPM) excluding all studies which randomised patients on the basis of ABPM. Change in sBP at 12 months. Change in sBP adjusted for age, sex, baseline clinic BP, history of diabetes, and level of intervention. Abbreviations: ABPM, ambulatory blood pressure monitoring; BP, blood pressure; sBP, systolic blood pressure. (TIFF)

S14 Fig. Primary analyses (ABPM) excluding all studies which randomised patients on the basis of clinic BP. Change in sBP at 12 months. Change in sBP adjusted for age, sex, baseline clinic BP, history of diabetes, and level of intervention. Abbreviations: ABPM, ambulatory blood pressure monitoring; BP, blood pressure; sBP, systolic blood pressure. (TIFF)

S15 Fig. Impact of self-monitoring of BP on the RR of uncontrolled BP at 12 months, with patients lost to follow-up assumed to have controlled BP (15 studies). RR of uncontrolled BP adjusted for age, sex, baseline clinic BP, and history of diabetes. Abbreviations: BP, blood pressure; RR, relative risk. (TIF)

S16 Fig. Impact of self-monitoring of BP on the RR of uncontrolled BP at 12 months, with patients lost to follow-up assumed to have uncontrolled BP (15 studies). RR of uncontrolled BP adjusted for age, sex, baseline clinic BP, and history of diabetes. Abbreviations: BP, blood pressure; RR, relative risk. (TIF)

S17 Fig. Impact of self-monitoring of BP on clinic sBP at 12 months, with patients who had controlled BP at baseline excluded (15 studies). Change in sBP adjusted for age, sex, baseline clinic BP, and history of diabetes. Abbreviations: BP, blood pressure; sBP, systolic blood pressure.

(TIF)

S18 Fig. Studies which measured change in medication at follow-up. sBP change at 12 months analysed without adjusting for medication changes at follow-up (11 studies). Change in sBP adjusted for age, sex, baseline clinic BP, and history of diabetes. Abbreviations: BP, blood pressure; sBP, systolic blood pressure.



S19 Fig. Studies which measured change in medication at follow-up. sBP change at 12 months analysed adjusting for medication changes at follow-up (11 studies). Change in sBP adjusted for age, sex, baseline clinic BP, history of diabetes, and medication changes at 12 months follow-up. Abbreviations: BP, blood pressure; sBP, systolic blood pressure. (TIF)

S20 Fig. Influence analysis presenting the pooled estimate of mean change in sBP at 12 months with each individual study omitted from the meta-analysis in turn. Each line indicates pooled meta-analysis results with that study omitted from the results. Abbreviation: sBP, systolic blood pressure.



S21 Fig. Funnel plot showing mean change in sBP at 12 months. The standard error is plotted against the mean change in sBP at 12 months. An Egger's test of zero (P = 1.00) would indicate little influence of publication bias. Abbreviation: sBP, systolic blood pressure. (TIFF)

S22 Fig. sBP change plotted against medication changes at 12 months follow-up, by level of intervention (11 studies). *Test for trend using a fixed-effects linear regression model adjusted for study. †The HOMERUS and TCYB trials, and studies by Godwin et al. [43] and Leiva et al. [46], were excluded due to missing data on medication changes at follow-up. Results where a negative change in BP is associated with a positive change in number of medications suggest medication intensification may be related to improved BP at 12 months. Abbreviation: BP, blood pressure; sBP, systolic blood pressure. (TIFF)

S23 Fig. The STATA code used for the meta-analysis. The STATA code used to perform the meta-analysis and figures. (DOCX)

Acknowledgments

The authors would like to thank Felicia McCant, MSSW (Durham, NC VA Medical Center, Durham, USA); Steve Asche, MA (HealthPartners Institute for Education and Research, Minneapolis, USA); Leah Tuzzio, MPH (Group Health Research Institute, Seattle, USA); Mark Butler, MA (Center for Healthful Behavior Change, New York, USA); Melissa L. Anderson, MS (Group Health Research Institute, Seattle, USA); Nichole Wagner, MPH (Institute for Health Research, Colorado, USA); and Shadi Chamany (New York City Department of Health & Mental Hygiene, New York, USA) for helping with data formatting and data queries. The views expressed are those of the author(s) and not necessarily those of the NIHR, the NHS, or the Department of Health.

Author Contributions

- **Conceptualization:** Emma P. Bray, F. D. Richard Hobbs, Jonathan Mant, Stefano Omboni, Richard J. McManus.
- Data curation: Katherine L. Tucker, James P. Sheppard, Hayden B. Bosworth, Alfred Bove, Kenneth Earle, Johnson George, Marshall Godwin, Beverly B. Green, Paul Hebert, Ilkka Kantola, Sally M. Kerry, Alfonso Leiva, David J. Magid, Karen L. Margolis, Brian McKinstry, Mary Ann McLaughlin, Stefano Omboni, Olugbenga Ogedegbe, Gianfranco Parati, Bahman P. Tabaei, Juha Varis, Willem J. Verberk, Bonnie J. Wakefield, Richard J. McManus.
- Formal analysis: Katherine L. Tucker, James P. Sheppard, Richard Stevens, Nashat Qamar, Richard J. McManus.
- **Funding acquisition:** Emma P. Bray, F. D. Richard Hobbs, Jonathan Mant, Richard J. McManus.

Investigation: Katherine L. Tucker, James P. Sheppard, Richard J. McManus.

Methodology: James P. Sheppard, Richard Stevens, Sally M. Kerry.

Project administration: Katherine L. Tucker.

Supervision: Richard Stevens, Richard J. McManus.

Validation: James P. Sheppard.

- Writing original draft: Katherine L. Tucker, James P. Sheppard, Richard J. McManus.
- Writing review & editing: Katherine L. Tucker, James P. Sheppard, Richard Stevens, Hayden B. Bosworth, Alfred Bove, Emma P. Bray, Kenneth Earle, Johnson George, Marshall Godwin, Beverly B. Green, Paul Hebert, F. D. Richard Hobbs, Ilkka Kantola, Sally M. Kerry, Alfonso Leiva, David J. Magid, Jonathan Mant, Karen L. Margolis, Brian McKinstry, Mary Ann McLaughlin, Stefano Omboni, Olugbenga Ogedegbe, Gianfranco Parati, Nashat Qamar, Bahman P. Tabaei, Juha Varis, Willem J. Verberk, Bonnie J. Wakefield, Richard J. McManus.

References

- Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009; 338: b1665. https://doi.org/10.1136/bmj.b1665 PMID: 19454737
- Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet. 1990; 335: 827–38. PMID: 1969567
- Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004; 43: 10–17. Epub 2003/11/26. https://doi.org/10.1161/01.HYP.0000103630.72812.10 PMID: 14638619
- Uhlig K, Patel K, Ip S, Kitsios GD, Balk EM. Self-measured blood pressure monitoring in the management of hypertension: a systematic review and meta-analysis. Ann Intern Med. 2013; 159: 185–94. Epub 2013/08/08. https://doi.org/10.7326/0003-4819-159-3-201308060-00008 PMID: 23922064
- Little P, Barnett J, Barnsley L, Marjoram J, Fitzgerald-Barron A, Mant D. Comparison of acceptability of and preferences for different methods of measuring blood pressure in primary care. BMJ. 2002; 325: 258–9. Epub 2002/08/03. PMID: 12153924

- Bobrie G, Chatellier G, Genes N, Clerson P, Vaur L, Vaisse B, et al. Cardiovascular prognosis of "masked hypertension" detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA. 2004; 291: 1342–9. https://doi.org/10.1001/jama.291.11.1342 PMID: 15026401
- Grant RW, Pandiscio JC, Pajolek H, Woulfe A, Pelletier A, Kvedar J, et al. Implementation of a webbased tool for patient medication self-management: the Medication Self-titration Evaluation Programme (Med-STEP) for blood pressure control. Inform Prim Care. 2012; 20: 57–67. Epub 2013/01/23. PMID: 23336836
- 8. Hypertension: the clinical management of primary hypertension in adults. (2011) NICE clinical guideline 127.
- Mengden T, Hernandez Medina RM, Beltran B, Alvarez E, Kraft K, Vetter H. Reliability of reporting selfmeasured blood pressure values by hypertensive patients. Am J Hypertens. 1998; 11: 1413–7. Epub 1999/01/08. PMID: 9880121
- Wagner S, Buus NH, Jespersen B, Ahrendt P, Bertelsen OW, Toftegaard TS. Measurement adherence in the blood pressure self-measurement room. Telemed J E Health. 2013; 19: 826–33. Epub 2013/05/ 02. https://doi.org/10.1089/tmj.2013.0032 PMID: 23631589
- Omboni S, Ferrari R. The role of telemedicine in hypertension management: focus on blood pressure telemonitoring. Curr Hypertens Rep. 2015; 17: 535. Epub 2015/03/21. https://doi.org/10.1007/s11906-015-0535-3 PMID: 25790799
- Fahey T, Schroeder K, Ebrahim S. Interventions used to improve control of blood pressure in patients with hypertension. Cochrane Database Syst Rev. 2005: CD005182. Epub 2005/01/18. https://doi.org/ 10.1002/14651858.CD005182 PMID: 15654709
- Cappuccio FP, Kerry SM, Forbes L, Donald A. Blood pressure control by home monitoring: meta-analysis of randomised trials. BMJ. 2004; 329: 145. Epub 2004/06/15. <u>https://doi.org/10.1136/bmj.38121.</u> 684410.AE PMID: 15194600
- Bray EP, Holder R, Mant J, McManus RJ. Does self-monitoring reduce blood pressure? Meta-analysis with meta-regression of randomized controlled trials. Ann Med. 2010; 42: 371–86. Epub 2010/05/28. https://doi.org/10.3109/07853890.2010.489567 PMID: 20504241
- Tucker KL, Sheppard JP, Stevens R, Bosworth HB, Bove A, Bray EP, et al. Individual patient data meta-analysis of self-monitoring of blood pressure (BP-SMART): a protocol. BMJ Open. 2015; 5: 008532.
- Mangesi L, Dowswell T. Treatments for breast engorgement during lactation. Cochrane Database Syst Rev. 2010: CD006946. Epub 2010/09/09. https://doi.org/10.1002/14651858.CD006946.pub2 PMID: 20824853
- Varis J, Kantola I. The choice of home blood pressure result reporting method is essential: Results mailed to physicians did not improve hypertension control compared with ordinary office-based blood pressure treatment. Blood Press. 2010; 19: 319–24. Epub 2010/04/07. https://doi.org/10.3109/ 08037051003718457 PMID: 20367560
- Artinian NT, Flack JM, Nordstrom CK, Hockman EM, Washington OG, Jen KL, et al. Effects of nursemanaged telemonitoring on blood pressure at 12-month follow-up among urban African Americans. Nurs Res. 2007; 56: 312–22. Epub 2007/09/12. https://doi.org/10.1097/01.NNR.0000289501.45284.6e PMID: 17846552
- Rudd P, Miller NH, Kaufman J, Kraemer HC, Bandura A, Greenwald G, et al. Nurse management for hypertension. A systems approach. Am J Hypertens. 2004; 17: 921–7. Epub 2004/10/16. <u>https://doi.org/10.1016/j.amjhyper.2004.06.006</u> PMID: 15485755
- Marquez-Contreras E, Martell-Claros N, Gil-Guillen V, de la Figuera-Von Wichmann M, Casado-Martinez JJ, Martin-de Pablos JL, et al. Efficacy of a home blood pressure monitoring programme on therapeutic compliance in hypertension: the EAPACUM-HTA study. J Hypertens. 2006; 24: 169–75. Epub 2005/12/07. PMID: 16331115
- Madsen LB, Kirkegaard P, Pedersen EB. Blood pressure control during telemonitoring of home blood pressure. A randomized controlled trial during 6 months. Blood Press. 2008; 17: 78–86. https://doi.org/ 10.1080/08037050801915468 PMID: 18568696
- Rinfret S, Lussier MT, Peirce A, Duhamel F, Cossette S, Lalonde L, et al. The impact of a multidisciplinary information technology-supported program on blood pressure control in primary care. Circ Cardiovasc Qual Outcomes. 2009; 2: 170–7. Epub 2009/12/25. https://doi.org/10.1161/CIRCOUTCOMES. 108.823765 PMID: 20031834
- Earle K. In people with poorly controlled hypertension, self-management including telemonitoring is more effective than usual care for reducing systolic blood pressure at 6 and 12 months. Evid Based Med. 2011; 16: 17–8. Epub 2010/11/27. https://doi.org/10.1136/ebm1148 PMID: 21109677

- McManus RJ, Mant J, Roalfe A, Oakes RA, Bryan S, Pattison HM, et al. Targets and self monitoring in hypertension: randomised controlled trial and cost effectiveness analysis. BMJ. 2005; 331: 493. Epub 2005/08/24. https://doi.org/10.1136/bmj.38558.393669.E0 PMID: 16115830
- Verberk WJ, Thien T, Kroon AA, Lenders JW, van Montfrans GA, Smit AJ, et al. Prevalence and persistence of masked hypertension in treated hypertensive patients. Am J Hypertens. 2007; 20: 1258–65. Epub 2007/12/01. https://doi.org/10.1016/j.amjhyper.2007.08.002 PMID: 18047914
- Bosworth HB, Olsen MK, McCant F, Harrelson M, Gentry P, Rose C, et al. Hypertension Intervention Nurse Telemedicine Study (HINTS): testing a multifactorial tailored behavioral/educational and a medication management intervention for blood pressure control. Am Heart J. 2007; 153: 918–24. Epub 2007/06/02. https://doi.org/10.1016/j.ahj.2007.03.004 PMID: 17540191
- Bosworth HB, Olsen MK, Grubber JM, Neary AM, Orr MM, Powers BJ, et al. Two self-management interventions to improve hypertension control: a randomized trial. Ann Intern Med. 2009; 151: 687–95. Epub 2009/11/19. PMID: 19920269
- Yu SM, Tzou WS, Lo WS, Kuo YH, Lee HT, Wu R. Regulation of alpha-amylase-encoding gene expression in germinating seeds and cultured cells of rice. Gene. 1992; 122: 247–53. Epub 1992/12/15. PMID: 1339378
- 29. Fisher D. Two-stage individual participant data meta-analysis and generalised forest plots. Stata Journal. 2015; 15: 369–96.
- Stergiou GS, Karpettas N, Destounis A, Tzamouranis D, Nasothimiou E, Kollias A, et al. Home blood pressure monitoring alone vs. combined clinic and ambulatory measurements in following treatmentinduced changes in blood pressure and organ damage. Am J Hypertens. 2014; 27: 184–92. Epub 2013/ 11/06. https://doi.org/10.1093/ajh/hpt206 PMID: 24190902
- Wakefield BJ, Holman JE, Ray A, Scherubel M, Adams MR, Hillis SL, et al. Effectiveness of home telehealth in comorbid diabetes and hypertension: a randomized, controlled trial. Telemed J E Health. 2011; 17: 254–61. Epub 2011/04/12. https://doi.org/10.1089/tmj.2010.0176 PMID: 21476945
- 32. Parati G, Omboni S, Compare A, Grossi E, Callus E, Venco A, et al. Blood pressure control and treatment adherence in hypertensive patients with metabolic syndrome: protocol of a randomized controlled study based on home blood pressure telemonitoring vs. conventional management and assessment of psychological determinants of adherence (TELEBPMET Study). Trials. 2013; 14: 22. Epub 2013/01/25. https://doi.org/10.1186/1745-6215-14-22 PMID: 23343138
- Parati G, Omboni S, Albini F, Piantoni L, Giuliano A, Revera M, et al. Home blood pressure telemonitoring improves hypertension control in general practice. The TeleBPCare study. J Hypertens. 2009; 27: 198–203. Epub 2009/01/17. PMID: 19145785
- Ogedegbe G, Tobin JN, Fernandez S, Cassells A, Diaz-Gloster M, Khalida C, et al. Counseling African Americans to Control Hypertension: cluster-randomized clinical trial main effects. Circulation. 2014; 129: 2044–51. Epub 2014/03/25. <u>https://doi.org/10.1161/CIRCULATIONAHA.113.006650</u> PMID: 24657991
- 35. McManus RJ, Mant J, Haque MS, Bray EP, Bryan S, Greenfield SM, et al. Effect of self-monitoring and medication self-titration on systolic blood pressure in hypertensive patients at high risk of cardiovascular disease: the TASMIN-SR randomized clinical trial. JAMA. 2014; 312: 799–808. Epub 2014/08/27. https://doi.org/10.1001/jama.2014.10057 PMID: 25157723
- McManus RJ, Mant J, Bray EP, Holder R, Jones MI, Greenfield S, et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet. 2010; 376: 163–72. Epub 2010/07/14. https://doi.org/10.1016/S0140-6736(10)60964-6 PMID: 20619448
- Margolis KL, Asche SE, Bergdall AR, Dehmer SP, Groen SE, Kadrmas HM, et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA. 2013; 310: 46–56. Epub 2013/07/04. https://doi.org/10.1001/jama.2013.6549 PMID: 23821088
- Magid DJ, Ho PM, Olson KL, Brand DW, Welch LK, Snow KE, et al. A multimodal blood pressure control intervention in 3 healthcare systems. Am J Manag Care. 2011; 17: e96–103. Epub 2011/07/21. PMID: 21774100
- Kerry SM, Markus HS, Khong TK, Cloud GC, Tulloch J, Coster D, et al. Home blood pressure monitoring with nurse-led telephone support among patients with hypertension and a history of stroke: a community-based randomized controlled trial. CMAJ. 2013; 185: 23–31. Epub 2012/11/07. https://doi.org/ 10.1503/cmaj.120832 PMID: 23128283
- Hebert PL, Sisk JE, Tuzzio L, Casabianca JM, Pogue VA, Wang JJ, et al. Nurse-led disease management for hypertension control in a diverse urban community: a randomized trial. J Gen Intern Med. 2012; 27: 630–9. Epub 2011/12/07. https://doi.org/10.1007/s11606-011-1924-1 PMID: 22143452

- Halme L, Vesalainen R, Kaaja M, Kantola I. Self-monitoring of blood pressure promotes achievement of blood pressure target in primary health care. Am J Hypertens. 2005; 18: 1415–20. Epub 2005/11/11. https://doi.org/10.1016/j.amjhyper.2005.05.017 PMID: 16280273
- 42. Green BB, Ralston JD, Fishman PA, Catz SL, Cook A, Carlson J, et al. Electronic Communications and Home Blood Pressure Monitoring (e-BP) study: Design, delivery, and evaluation framework. Contemp Clin Trials. 2008; 29: 376–95. https://doi.org/10.1016/j.cct.2007.09.005 PMID: 17974502
- 43. Godwin M, Lam M, Birtwhistle R, Delva D, Seguin R, Casson I, et al. A primary care pragmatic cluster randomized trial of the use of home blood pressure monitoring on blood pressure levels in hypertensive patients with above target blood pressure. Fam Pract. 2010; 27: 135–42. Epub 2009/12/25. https://doi.org/10.1093/fampra/cmp094 PMID: 20032170
- Bove AA, Homko CJ, Santamore WP, Kashem M, Kerper M, Elliott DJ. Managing hypertension in urban underserved subjects using telemedicine—a clinical trial. Am Heart J. 2013; 165: 615–21. Epub 2013/ 03/30. https://doi.org/10.1016/j.ahj.2013.01.004 PMID: 23537980
- McKinstry B, Hanley J, Wild S, Pagliari C, Paterson M, Lewis S, et al. Telemonitoring based service redesign for the management of uncontrolled hypertension: multicentre randomised controlled trial. BMJ. 2013; 346: f3030. Epub 2013/05/28. https://doi.org/10.1136/bmj.f3030 PMID: 23709583
- 46. Leiva A, Aguilo A, Fajo-Pascual M, Moreno L, Martin MC, Garcia EM, et al. Efficacy of a brief multifactorial adherence-based intervention in reducing blood pressure: a randomized clinical trial. Patient Prefer Adherence. 2014; 8: 1683–90. Epub 2014/12/20. https://doi.org/10.2147/PPA.S66927 PMID: 25525344
- 47. Yi SS, Tabaei BP, Angell SY, Rapin A, Buck MD, Pagano WG, et al. Self-blood pressure monitoring in an urban, ethnically diverse population: a randomized clinical trial utilizing the electronic health record. Circ Cardiovasc Qual Outcomes. 2015; 8: 138–45. Epub 2015/03/05. <u>https://doi.org/10.1161/ CIRCOUTCOMES.114.000950 PMID: 25737487</u>
- Stewart K, George J, Mc Namara KP, Jackson SL, Peterson GM, Bereznicki LR, et al. A multifaceted pharmacist intervention to improve antihypertensive adherence: a cluster-randomized, controlled trial (HAPPy trial). J Clin Pharm Ther. 2014; 39: 527–34. Epub 2014/06/20. https://doi.org/10.1111/jcpt. 12185 PMID: 24943987
- Kim KB, Han HR, Huh B, Nguyen T, Lee H, Kim MT. The effect of a community-based self-help multimodal behavioral intervention in Korean American seniors with high blood pressure. Am J Hypertens. 2014; 27: 1199–208. Epub 2014/03/29. https://doi.org/10.1093/ajh/hpu041 PMID: 24671049
- Magid DJ, Olson KL, Billups SJ, Wagner NM, Lyons EE, Kroner BA. A pharmacist-led, American Heart Association Heart360 Web-enabled home blood pressure monitoring program. Circ Cardiovasc Qual Outcomes. 2013; 6: 157–63. Epub 2013/03/07. <u>https://doi.org/10.1161/CIRCOUTCOMES.112.968172</u> PMID: 23463811
- Green BB, Anderson ML, Cook AJ, Catz S, Fishman PA, McClure JB, et al. e-Care for heart wellness: a feasibility trial to decrease blood pressure and cardiovascular risk. Am J Prev Med. 2014; 46: 368–77. Epub 2014/03/22. https://doi.org/10.1016/j.amepre.2013.11.009 PMID: 24650839
- Sterne JA, White IR, Carlin JB, Spratt M, Royston P, Kenward MG, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009; 338: b2393. Epub 2009/ 07/01. https://doi.org/10.1136/bmj.b2393 PMID: 19564179
- Agarwal R, Bills JE, Hecht TJ, Light RP. Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and meta-analysis. Hypertension. 2011; 57: 29–38. Epub 2010/12/01. https://doi.org/10.1161/HYPERTENSIONAHA.110.160911 PMID: 21115879
- Fletcher BR, Hartmann-Boyce J, Hinton L, McManus RJ. The Effect of Self-Monitoring of Blood Pressure on Medication Adherence and Lifestyle Factors: A Systematic Review and Meta-Analysis. Am J Hypertens. 2015; 28: 1209–21. Epub 2015/03/01. https://doi.org/10.1093/ajh/hpv008 PMID: 25725092
- Omboni S, Gazzola T, Carabelli G, Parati G. Clinical usefulness and cost effectiveness of home blood pressure telemonitoring: meta-analysis of randomized controlled studies. J Hypertens. 2013; 31: 455– 67; discussion 467–8. Epub 2013/01/10. <u>https://doi.org/10.1097/HJH.0b013e32835ca8dd</u> PMID: 23299557
- 56. Wald DS, Law M, Mills S, Bestwick JP, Morris JK, Wald NJ. A 16-week, randomized, double-blind, placebo-controlled, crossover trial to quantify the combined effect of an angiotensin-converting enzyme inhibitor and a beta-blocker on blood pressure reduction. Clin Ther. 2008; 30: 2030–9. Epub 2008/12/ 26. https://doi.org/10.1016/j.clinthera.2008.11.003 PMID: 19108791
- Group SR, Wright JT Jr., Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015; 373: 2103–16. https://doi.org/ 10.1056/NEJMoa1511939 PMID: 26551272

- Baral-Grant S, Haque MS, Nouwen A, Greenfield SM, McManus RJ. Self-Monitoring of Blood Pressure in Hypertension: A UK Primary Care Survey. Int J Hypertens. 2012; 2012: 582068. Epub 2011/10/21. https://doi.org/10.1155/2012/582068 PMID: 22013510
- 59. Joffres M, Falaschetti E, Gillespie C, Robitaille C, Loustalot F, Poulter N, et al. Hypertension prevalence, awareness, treatment and control in national surveys from England, the USA and Canada, and correlation with stroke and ischaemic heart disease mortality: a cross-sectional study. BMJ Open. 2013; 3: e003423. Epub 2013/09/03. https://doi.org/10.1136/bmjopen-2013-003423 PMID: 23996822